PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17593275-5 2007 Newer agents based on enhancing incretin activity, including the glucagon-like peptide-1 mimetics exenatide and liraglutide and the oral dipeptidyl peptidase-4 inhibitors sitagliptin and vildagliptin, may offer particular advantages in elderly patients with diabetes. Vildagliptin 187-199 dipeptidyl peptidase 4 Homo sapiens 137-159 17593276-3 2007 Vildagliptin is a potent and selective oral DPP-4 inhibitor that has been studied both as monotherapy and in combination with other antidiabetic treatments. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 44-49 17593276-7 2007 These results suggest that vildagliptin, as a member of the novel class of DPP-4 inhibitors, has the potential to significantly change the clinical management of diabetes. Vildagliptin 27-39 dipeptidyl peptidase 4 Homo sapiens 75-80 17660482-1 2007 Vildagliptin is a novel antidiabetic agent that is an orally active, potent, and selective inhibitor of dipeptidyl peptidase IV, the enzyme responsible for degradation of the incretin hormones. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 104-127 17559747-8 2007 Initial clinical trial experience with the new oral DPP-4 inhibitors such as sitagliptin and vildagliptin suggests that these agents are weight-neutral, while providing improved glycaemic control when added to metformin. Vildagliptin 93-105 dipeptidyl peptidase 4 Homo sapiens 52-57 17559747-10 2007 Initial clinical trial experience with oral DPP-4 inhibitors such as sitagliptin and vildagliptin suggest that these agents may represent an important oral treatment option for weight-neutral, glycaemic control when added to metformin. Vildagliptin 85-97 dipeptidyl peptidase 4 Homo sapiens 44-49 17486328-0 2007 The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Vildagliptin 109-121 dipeptidyl peptidase 4 Homo sapiens 67-90 17486328-0 2007 The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Vildagliptin 109-121 dipeptidyl peptidase 4 Homo sapiens 92-97 17486328-1 2007 OBJECTIVE: Vildagliptin is a potent and selective dipeptidyl peptidase-IV (DPP-4) inhibitor that improves glycemic control in patients with type 2 diabetes mellitus by increasing alpha- and beta-cell responsiveness to glucose. Vildagliptin 11-23 dipeptidyl peptidase 4 Homo sapiens 50-73 17486328-1 2007 OBJECTIVE: Vildagliptin is a potent and selective dipeptidyl peptidase-IV (DPP-4) inhibitor that improves glycemic control in patients with type 2 diabetes mellitus by increasing alpha- and beta-cell responsiveness to glucose. Vildagliptin 11-23 dipeptidyl peptidase 4 Homo sapiens 75-80 17848846-7 2007 The oral DPP-4 inhibitors vildagliptin, sitagliptin, and saxagliptin are efficacious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose. Vildagliptin 26-38 dipeptidyl peptidase 4 Homo sapiens 9-14 17563048-2 2007 SUMMARY: Vildagliptin is an agent in a new class of medications called dipeptidyl peptidase IV (DPP4) inhibitors. Vildagliptin 9-21 dipeptidyl peptidase 4 Homo sapiens 71-94 17563048-2 2007 SUMMARY: Vildagliptin is an agent in a new class of medications called dipeptidyl peptidase IV (DPP4) inhibitors. Vildagliptin 9-21 dipeptidyl peptidase 4 Homo sapiens 96-100 17563048-3 2007 By inhibiting DPP4, vildagliptin causes an increase in glucagon like peptide-1 (GLP-1), an intestinal hormone that aids in glucose homeostasis and insulin secretion. Vildagliptin 20-32 dipeptidyl peptidase 4 Homo sapiens 14-18 17563048-5 2007 Vildagliptin has a halflife of about 90 minutes; however, > or =50% of DPP4 inhibition continues for more than 10 hours, allowing for once- or twice-daily dosing. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 74-78 17456545-1 2007 OBJECTIVE: To highlight the role of incretin hormones in the management of type 2 diabetes mellitus with a focus on vildagliptin, a dipeptidyl peptidase IV (DPP IV) inhibitor currently in development. Vildagliptin 116-128 dipeptidyl peptidase 4 Homo sapiens 132-155 17387446-3 2007 Vildagliptin is a dipeptidyl peptidase-IV inhibitor, which improves glycaemic control by increasing pancreatic beta cell responsiveness to glucose and suppressing inappropriate glucagon secretion. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 18-41 17456545-1 2007 OBJECTIVE: To highlight the role of incretin hormones in the management of type 2 diabetes mellitus with a focus on vildagliptin, a dipeptidyl peptidase IV (DPP IV) inhibitor currently in development. Vildagliptin 116-128 dipeptidyl peptidase 4 Homo sapiens 157-163 17456545-8 2007 Studies evaluating the use of vildagliptin in patients with type 2 diabetes found significant decreases in DPP IV and increased GLP-1 activity 45 minutes after dosing. Vildagliptin 30-42 dipeptidyl peptidase 4 Homo sapiens 107-113 17456545-14 2007 CONCLUSIONS: Vildagliptin represents a safe and effective new approach to targeting GLP-1 deficiencies in patients with type 2 diabetes by inhibiting DPP IV. Vildagliptin 13-25 dipeptidyl peptidase 4 Homo sapiens 150-156 17519080-0 2007 Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Vildagliptin 59-71 dipeptidyl peptidase 4 Homo sapiens 25-48 17519080-1 2007 OBJECTIVE: Vildagliptin is a potent and selective dipeptidyl peptidase-IV (DPP-4) inhibitor that improves glycemic control in patients with type 2 diabetes by increasing alpha and beta-cell responsiveness to glucose. Vildagliptin 11-23 dipeptidyl peptidase 4 Homo sapiens 50-73 17519080-1 2007 OBJECTIVE: Vildagliptin is a potent and selective dipeptidyl peptidase-IV (DPP-4) inhibitor that improves glycemic control in patients with type 2 diabetes by increasing alpha and beta-cell responsiveness to glucose. Vildagliptin 11-23 dipeptidyl peptidase 4 Homo sapiens 75-80 17244786-0 2007 The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. Vildagliptin 38-50 dipeptidyl peptidase 4 Homo sapiens 4-27 17277036-1 2007 OBJECTIVE: We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes. Vildagliptin 60-72 dipeptidyl peptidase 4 Homo sapiens 80-102 17353295-21 2007 In preclinical studies, oral active DPP-IV inhibitors (sitagliptin and vildagliptin) also promoted beta-cell proliferation, neogenesis, and inhibition of apoptosis in rodents. Vildagliptin 71-83 dipeptidyl peptidase 4 Homo sapiens 36-42 17244786-1 2007 AIMS/HYPOTHESIS: Vildagliptin is a selective dipeptidyl peptidase IV inhibitor that augments meal-stimulated levels of biologically active glucagon-like peptide-1. Vildagliptin 17-29 dipeptidyl peptidase 4 Homo sapiens 45-68 17300591-5 2007 DPP-IV inhibitors such as vildagliptin and sitagliptin have been shown to be highly effective antihyperglycaemic agents that augment insulin secretion and reduce glucagon secretion via glucose-dependent mechanisms. Vildagliptin 26-38 dipeptidyl peptidase 4 Homo sapiens 0-6 17300592-1 2007 AIM: The purpose of this study was to assess the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor vildagliptin in combination with the thiazolidinedione (TZD) pioglitazone in patients with type 2 diabetes (T2DM). Vildagliptin 115-127 dipeptidyl peptidase 4 Homo sapiens 82-104 16816950-1 2006 AIMS/HYPOTHESIS: We assessed the effects of vildagliptin, a novel dipeptidyl peptidase IV inhibitor, on postprandial lipid and lipoprotein metabolism in patients with type 2 diabetes. Vildagliptin 44-56 dipeptidyl peptidase 4 Homo sapiens 66-89 17596103-1 2007 BACKGROUND: Vildagliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor currently under development for the treatment of type 2 diabetes mellitus. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 30-53 17596103-1 2007 BACKGROUND: Vildagliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor currently under development for the treatment of type 2 diabetes mellitus. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 55-60 17596103-7 2007 Vildagliptin inhibited DPP-4 (>90%) at all doses and demonstrated a dose-dependent effect on the duration of inhibition. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 23-28 17596103-11 2007 CONCLUSION: Vildagliptin is likely to be a useful therapy for patients with type 2 diabetes based on the inhibition of DPP-4 and the subsequent increase in incretin hormones, GLP-1 and GIP, and the decrease in glucose and glucagon levels. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 119-124 17379930-11 2007 Clinical studies with the oral DPPIV inhibitors sitagliptin and vildagliptin show promising results, but are only published as abstracts at scientific meetings. Vildagliptin 64-76 dipeptidyl peptidase 4 Homo sapiens 31-36 17713976-0 2007 The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Vildagliptin 126-138 dipeptidyl peptidase 4 Homo sapiens 92-114 17713976-1 2007 BACKGROUND AND OBJECTIVE: Vildagliptin is a potent, selective, orally active inhibitor of dipeptidylpeptidase-IV being developed for the treatment of type 2 diabetes mellitus. Vildagliptin 26-38 dipeptidyl peptidase 4 Homo sapiens 90-112 17098089-5 2006 Orally administered DPP-4 inhibitors, such as sitagliptin and vildagliptin, reduce HbA1c by 0.5-1.0%, with few adverse events and no weight gain. Vildagliptin 62-74 dipeptidyl peptidase 4 Homo sapiens 20-25 16823726-0 2006 Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Vildagliptin 49-61 dipeptidyl peptidase 4 Homo sapiens 33-38 16969429-0 2006 Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 22-27 16969429-5 2006 Vildagliptin is a potent, orally active, highly selective DPP-4 inhibitor that enhances the antidiabetic actions of the incretins. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 58-63 16682937-12 2006 DPP-4-inhibitors (e.g. Vildagliptin), Sitagliptin and Saxagliptin) that inhibit the enzyme DPP-4 responsible for incretin degradation are also under study. Vildagliptin 23-35 dipeptidyl peptidase 4 Homo sapiens 0-5 16682937-12 2006 DPP-4-inhibitors (e.g. Vildagliptin), Sitagliptin and Saxagliptin) that inhibit the enzyme DPP-4 responsible for incretin degradation are also under study. Vildagliptin 23-35 dipeptidyl peptidase 4 Homo sapiens 91-96 16548792-0 2006 Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 30-52 16548792-1 2006 Vildagliptin is a competitive and reversible inhibitor of dipeptidyl peptidase-4. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 58-80 16823726-2 2006 This twelve-week randomized, double-masked, placebo-controlled study assessed the efficacy and tolerability of the specific and potent oral dipeptidyl peptidase-4 inhibitor, vildagliptin (25 mg, bid, n=70) VS. placebo (bid, n=28) in previously diet-treated subjects with type 2 diabetes. Vildagliptin 174-186 dipeptidyl peptidase 4 Homo sapiens 140-162 17100408-1 2006 Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is being evaluated in the treatment of patients with type 2 diabetes mellitus. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 18-40 17100408-1 2006 Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is being evaluated in the treatment of patients with type 2 diabetes mellitus. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 42-47 16219012-0 2005 Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Vildagliptin 100-112 dipeptidyl peptidase 4 Homo sapiens 32-54 16219012-2 2005 This study was designed to establish a dose of the DPP-4-inhibitor vildagliptin (LAF237) that was effective in reducing HbA1c levels and was safe and well tolerated in patients with type 2 diabetes. Vildagliptin 67-79 dipeptidyl peptidase 4 Homo sapiens 51-56 34577104-2 2021 Vildagliptin belongs to relatively new oral antidiabetic drugs named gliptins, inhibiting dipeptidyl peptidase 4 (DPP-4) and prolonging the activities of the endogenous incretin hormones. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 90-112 17491680-13 2005 Dipeptidyl-peptidase IV inhibitors (DPP-IV inhibitors; e.g. Vildagliptin, Sitagliptin) that inhibit the enzyme responsible for incretin degradation are also under study. Vildagliptin 60-72 dipeptidyl peptidase 4 Homo sapiens 36-42 16318402-13 2005 Dipeptidyl peptidase-IV inhibitors (e.g. vildagliptin, sitagliptin, and saxagliptin) that inhibit the enzyme responsible for incretin degradation are also being studied. Vildagliptin 41-53 dipeptidyl peptidase 4 Homo sapiens 0-23 16043735-0 2005 Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Vildagliptin 106-118 dipeptidyl peptidase 4 Homo sapiens 72-95 16043735-11 2005 CONCLUSIONS: This study presents evidence that DPP-4 inhibition by vildagliptin when added to metformin in type 2 diabetes over 52 weeks improves beta-cell function along with improved postmeal insulin sensitivity. Vildagliptin 67-79 dipeptidyl peptidase 4 Homo sapiens 47-52 15886245-0 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 16-39 15886245-1 2005 AIMS/HYPOTHESIS: The dipeptidyl peptidase IV inhibitor, vildagliptin, increases levels of intact glucagon-like peptide-1 (GLP-1) and improves glycemic control in patients with type 2 diabetes. Vildagliptin 56-68 dipeptidyl peptidase 4 Homo sapiens 21-44 15907807-0 2005 Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Vildagliptin 70-82 dipeptidyl peptidase 4 Homo sapiens 14-37 15907807-0 2005 Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Vildagliptin 84-156 dipeptidyl peptidase 4 Homo sapiens 14-37 34577104-2 2021 Vildagliptin belongs to relatively new oral antidiabetic drugs named gliptins, inhibiting dipeptidyl peptidase 4 (DPP-4) and prolonging the activities of the endogenous incretin hormones. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 114-119 34484112-1 2021 Purpose: Dipeptidylpeptidase-4 (DPP-4) inhibitors, including linagliptin, alogliptin, saxagliptin, sitagliptin, and vildagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM) patients in China. Vildagliptin 116-128 dipeptidyl peptidase 4 Homo sapiens 9-30 34384428-10 2021 After MCDA, the overall value orders for each DPP-4 inhibitor included Sitagliptin (0.45), Linagliptin (0.44), Vildagliptin (0.43), Alogliptin (0.42) and Saxagliptin (0.40). Vildagliptin 111-123 dipeptidyl peptidase 4 Homo sapiens 46-51 34484112-1 2021 Purpose: Dipeptidylpeptidase-4 (DPP-4) inhibitors, including linagliptin, alogliptin, saxagliptin, sitagliptin, and vildagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM) patients in China. Vildagliptin 116-128 dipeptidyl peptidase 4 Homo sapiens 32-37 33068301-10 2021 CONCLUSIONS: DPP-4 inhibitors, saxagliptin and vildagliptin, resulted in substantial reductions in albuminuria in patients with T2D and hypertension on top of RAAS blockade after short term therapy independently on glycemic or hemodynamic changes. Vildagliptin 47-59 dipeptidyl peptidase 4 Homo sapiens 13-18 35216503-0 2022 Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson"s Disease. Vildagliptin 46-58 dipeptidyl peptidase 4 Homo sapiens 31-35 35216503-4 2022 Vildagliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, is an anti-diabetic drug with various pharmacological properties including neuroprotective effects. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 16-38 35216503-4 2022 Vildagliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, is an anti-diabetic drug with various pharmacological properties including neuroprotective effects. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 40-44 35272176-1 2022 BACKGROUND AND AIMS: Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor to treat type 2 diabetes mellitus, is available as immediate release (IR) tablets administered at 50 mg twice daily (BID). Vildagliptin 21-33 dipeptidyl peptidase 4 Homo sapiens 37-59 35272176-1 2022 BACKGROUND AND AIMS: Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor to treat type 2 diabetes mellitus, is available as immediate release (IR) tablets administered at 50 mg twice daily (BID). Vildagliptin 21-33 dipeptidyl peptidase 4 Homo sapiens 61-66 35272176-11 2022 CONCLUSION: This study confirms the therapeutic equivalence of vildagliptin IR and MR formulations for DPP-4 enzyme inhibition over time. Vildagliptin 63-75 dipeptidyl peptidase 4 Homo sapiens 103-108 35370321-1 2022 Vildagliptin is an oral agent which is a member of a new class of hypoglycemic drugs, dipeptidylpeptidase-4 (DPP-4) inhibitors. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 86-107 35370321-1 2022 Vildagliptin is an oral agent which is a member of a new class of hypoglycemic drugs, dipeptidylpeptidase-4 (DPP-4) inhibitors. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 109-114 32242496-9 2021 The catalytic domain of Dipeptidyl peptidase IV enzyme in complex with Vildagliptin (PDB Code: 6B1E) was obtained from protein data bank with resolution 1.77 A . Vildagliptin 71-83 dipeptidyl peptidase 4 Homo sapiens 24-47 32310854-1 2021 BACKGROUND: Vildagliptin, an oral antidiabetic of the dipeptidyl peptidase-4 (DPP-4) inhibitor drugs, exhibits an overall low risk of hypoglycemia with less frequent hypoglycemic events in type 2 diabetes mellitus (T2DM) patients than other conventional antidiabetic drugs. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 54-76 33573656-10 2021 CONCLUSIONS: This study revealed that treatment with dipeptidyl-peptidase 4 inhibitors, especially vildagliptin, is significantly associated with an increased risk of bullous pemphigoid development. Vildagliptin 99-111 dipeptidyl peptidase 4 Homo sapiens 53-75 32310854-1 2021 BACKGROUND: Vildagliptin, an oral antidiabetic of the dipeptidyl peptidase-4 (DPP-4) inhibitor drugs, exhibits an overall low risk of hypoglycemia with less frequent hypoglycemic events in type 2 diabetes mellitus (T2DM) patients than other conventional antidiabetic drugs. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 78-83 32956689-0 2020 Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38alpha, and NF-kappaB signaling. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 16-21 33050169-13 2020 Paired comparisons showed that, during the postprandial period, vildagliptin significantly changed levels of insulin and glucagon-like peptide-1, and also the dipeptidyl peptidase-4 activity, while metformin had effects on plasma glucose solely. Vildagliptin 64-76 dipeptidyl peptidase 4 Homo sapiens 159-181 32731178-0 2020 Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 21-25 32731178-0 2020 Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 16-20 32731178-9 2020 RESULTS: Vildagliptin effectively attenuated inflammation and fibrosis in bleomycin-induced pulmonary tissue via inhibiting the activity of CD26/DPP4. Vildagliptin 9-21 dipeptidyl peptidase 4 Homo sapiens 140-144 32731178-9 2020 RESULTS: Vildagliptin effectively attenuated inflammation and fibrosis in bleomycin-induced pulmonary tissue via inhibiting the activity of CD26/DPP4. Vildagliptin 9-21 dipeptidyl peptidase 4 Homo sapiens 145-149 32731178-12 2020 CONCLUSION: As an inhibitor of CD26/DPP4, Vildagliptin could be a promising therapeutic candidate for idiopathic pulmonary fibrosis. Vildagliptin 42-54 dipeptidyl peptidase 4 Homo sapiens 31-35 32731178-12 2020 CONCLUSION: As an inhibitor of CD26/DPP4, Vildagliptin could be a promising therapeutic candidate for idiopathic pulmonary fibrosis. Vildagliptin 42-54 dipeptidyl peptidase 4 Homo sapiens 36-40 32218354-2 2020 Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 36-58 32982353-4 2020 The aim of this study was to investigate the effects of vildagliptin, a DPP-4 inhibitor, compared with glibenclamide in GV and endothelial function in patients with T2DM and arterial hypertension. Vildagliptin 56-68 dipeptidyl peptidase 4 Homo sapiens 72-77 32873667-2 2020 The objective of this study was to test whether glycaemic response to representative treatments of dipeptidyl peptidase-4 inhibitors (vildagliptin) and thiazolidinediones (pioglitazone) varies according to ethnicity, gender, baseline obesity, triglyceride level or genetic variation. Vildagliptin 134-146 dipeptidyl peptidase 4 Homo sapiens 99-121 32746479-1 2020 BACKGROUND: Vildagliptin is an antidiabetic agent, belongs to the dipeptidyl peptidase IV (DPP-4) inhibitors. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 66-89 32746479-1 2020 BACKGROUND: Vildagliptin is an antidiabetic agent, belongs to the dipeptidyl peptidase IV (DPP-4) inhibitors. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 91-96 32228183-1 2020 Objectives: The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin is indicated for type 2 diabetes mellitus (T2DM). Vildagliptin 57-69 dipeptidyl peptidase 4 Homo sapiens 16-38 32228183-1 2020 Objectives: The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin is indicated for type 2 diabetes mellitus (T2DM). Vildagliptin 57-69 dipeptidyl peptidase 4 Homo sapiens 40-45 32218354-2 2020 Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 60-65 31885117-5 2020 Among the DPP-4 inhibitors available in Taiwan, vildagliptin showed the highest risk of BP (aHR, 2.849; 95% CI, 1.893-4.215; P < 0.001), followed by saxagliptin (aHR, 2.657; 95% CI, 1.770-3.934; P < 0.001). Vildagliptin 48-60 dipeptidyl peptidase 4 Homo sapiens 10-15 31885117-7 2020 This study revealed that treatment with DPP-4 inhibitors, especially vildagliptin, was significantly associated with an increased risk of BP among DM patients. Vildagliptin 69-81 dipeptidyl peptidase 4 Homo sapiens 40-45 30945564-4 2019 In this study, we investigated the molecular mechanism of the clinically available DPP-4 inhibitor vildagliptin in the protection of FFA-induced endothelial dysfunction. Vildagliptin 99-111 dipeptidyl peptidase 4 Homo sapiens 83-88 32014700-3 2020 Therefore, this study aimed to investigate vildagliptin, a DPP-4 inhibitor, effects on cognitive function in older patients with DM. Vildagliptin 43-55 dipeptidyl peptidase 4 Homo sapiens 59-64 32093712-10 2020 According to the measurement of glucose and insulin tolerance and glucose uptake abilities, we found that the overexpression of miR-214 could be used to alleviate IR in the IR models, especially when collaboratively used with DPP4 inhibitor vildagliptin. Vildagliptin 241-253 dipeptidyl peptidase 4 Homo sapiens 226-230 31689132-1 2020 Background: Vildagliptin is a dipeptidyl peptidase-4 inhibitor that reduces glycemia in patients with type 2 diabetes mellitus (T2DM). Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 30-52 31792328-4 2019 Among five DPP4 inhibitors, only two of them, vildagliptin and saxagliptin, exhibited apparent cytotoxic effects on myeloma cell lines, without any difference in suppression of DPP4 activity. Vildagliptin 46-58 dipeptidyl peptidase 4 Homo sapiens 11-15 31275243-8 2019 Five of the DPP-4 inhibitors (sitagliptin, vildagliptin, alogliptin, saxagliptin and linagliptin) were approved by regulatory authorities and entered the market between 2006 and 2013. Vildagliptin 43-55 dipeptidyl peptidase 4 Homo sapiens 12-17 31026379-5 2019 Here, we report a novel pharmacological role of the DPP-4 inhibitor vildagliptin in chondrocyte senescence. Vildagliptin 68-80 dipeptidyl peptidase 4 Homo sapiens 52-57 31026379-7 2019 The inhibition of DPP-4 by vildagliptin ameliorates TNF-alpha-induced chondrocyte senescence as determined by cellular senescence-associated beta-galactosidase (SA-beta-Gal) activity. Vildagliptin 27-39 dipeptidyl peptidase 4 Homo sapiens 18-23 31324296-5 2019 Vildagliptin (VI) is a potent DPP-4 inhibitor with least adverse events compared to other DPP-4 inhibitors. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 30-35 31324296-5 2019 Vildagliptin (VI) is a potent DPP-4 inhibitor with least adverse events compared to other DPP-4 inhibitors. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 90-95 31324296-5 2019 Vildagliptin (VI) is a potent DPP-4 inhibitor with least adverse events compared to other DPP-4 inhibitors. Vildagliptin 14-16 dipeptidyl peptidase 4 Homo sapiens 30-35 30519910-0 2019 Vildagliptin, an Anti-diabetic Drug of the DPP-4 Inhibitor, Induces Vasodilation via Kv Channel and SERCA Pump Activation in Aortic Smooth Muscle. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 43-48 31275298-11 2019 The association between the use of DPP-4is, particularly vildagliptin, and BP risk has been confirmed by several epidemiological studies. Vildagliptin 57-69 dipeptidyl peptidase 4 Homo sapiens 35-40 31164969-8 2019 DPPIV-bound STB-EVs from normal perfused placentae are dose dependently inhibited with vildagliptin. Vildagliptin 87-99 dipeptidyl peptidase 4 Homo sapiens 0-5 30828846-0 2019 Randomised clinical trial: the DPP-4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon-like peptide-1 plasma levels in healthy volunteers. Vildagliptin 48-60 dipeptidyl peptidase 4 Homo sapiens 31-36 30567879-1 2019 The O-glucuronide of vildagliptin, a dipeptidyl peptidase 4 inhibitor, is a major metabolite in monkeys and a minor metabolite in humans, rats, and dogs. Vildagliptin 21-33 dipeptidyl peptidase 4 Homo sapiens 37-59 30624566-11 2019 The use of DPP-4 inhibitors was associated with a significant increase in the risk of developing BP (adjusted odds ratio [aOR], 1.58; 95% CI, 1.25-2.00; P < .001); among all DPP-4 inhibitors used in Korea, the highest aOR was associated with the use of vildagliptin (aOR, 1.81; 95% CI, 1.31-2.50; P < .001). Vildagliptin 256-268 dipeptidyl peptidase 4 Homo sapiens 11-16 30444033-1 2019 The dipeptidyl peptidase 4 inhibitor vildagliptin (VLD), a widely used anti-diabetic drug, exerts favourable effects on vascular endothelium in diabetes. Vildagliptin 37-49 dipeptidyl peptidase 4 Homo sapiens 4-26 30624566-12 2019 Subgroup analyses revealed a significant association in male patients (aOR, 1.91; 95% CI, 1.39-2.63; P < .001) and that vildagliptin was the most high-risk DPP-4 inhibitor (aOR, 2.70; 95% CI, 1.73-4.34; P < .001). Vildagliptin 123-135 dipeptidyl peptidase 4 Homo sapiens 159-164 30624566-14 2019 Of the DPP-4 inhibitors available in Korea, vildagliptin was associated with the highest risk, particularly in male patients. Vildagliptin 44-56 dipeptidyl peptidase 4 Homo sapiens 7-12 30624566-15 2019 Practitioners should consider that DPP-4 inhibitors, particularly vildagliptin, may be associated with the development of BP in patients with diabetes. Vildagliptin 66-78 dipeptidyl peptidase 4 Homo sapiens 35-40 31169082-7 2019 Pharmacovigilance and cohort studies have revealed that DPP4is, especially vildagliptin, teneligliptin, and linagliptin, are a potential risk factor for BP onset. Vildagliptin 75-87 dipeptidyl peptidase 4 Homo sapiens 56-60 30452909-1 2019 In the present study, we investigated the effects of the specific DPP-4 inhibitor vildagliptin on degradation of type II collagen and aggrecan, the main components of the articular extracellular matrix, in primary human chondrocytes. Vildagliptin 82-94 dipeptidyl peptidase 4 Homo sapiens 66-71 29679391-2 2018 In addition to anti-diabetic effects, the five most widely used DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) also exert cardiovascular protective effects. Vildagliptin 95-107 dipeptidyl peptidase 4 Homo sapiens 64-69 31204117-0 2019 Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment. Vildagliptin 11-23 dipeptidyl peptidase 4 Homo sapiens 27-32 31204117-4 2019 This retrospective study investigated the effect of vildagliptin, an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), on the cognitive functioning of elderly diabetic patients with mild cognitive impairment (MCI) documented at mini mental state examination (MMSE). Vildagliptin 52-64 dipeptidyl peptidase 4 Homo sapiens 93-115 31204117-4 2019 This retrospective study investigated the effect of vildagliptin, an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), on the cognitive functioning of elderly diabetic patients with mild cognitive impairment (MCI) documented at mini mental state examination (MMSE). Vildagliptin 52-64 dipeptidyl peptidase 4 Homo sapiens 117-122 30123993-2 2019 Vildagliptin (VG), a dipeptidyl peptidase IV (DPP IV) inhibitor, is an anti-diabetic drug, which increases beta cell mass. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 21-44 30123993-2 2019 Vildagliptin (VG), a dipeptidyl peptidase IV (DPP IV) inhibitor, is an anti-diabetic drug, which increases beta cell mass. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 46-52 30557974-2 2018 While acute pancreatitis cases induced by saxagliptin, sitagliptin, and vildagliptin (all of which are members of the dipeptidyl peptidase-4 group) have been reported, there is no clear evidence suggesting that linagliptin may cause pancreatitis, and information in this regard is limited to a few studies. Vildagliptin 72-84 dipeptidyl peptidase 4 Homo sapiens 118-140 31336466-19 2019 Overall, amongst oral hypoglycemic agents, the combination of metformin and DPP4 inhibitors (Vildagliptin, Sitagliptin) was being prescribed majorly i.e 16.41%. Vildagliptin 93-105 dipeptidyl peptidase 4 Homo sapiens 76-80 29607626-0 2019 Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase-4 inhibitor vildagliptin. Vildagliptin 102-114 dipeptidyl peptidase 4 Homo sapiens 69-91 29607626-1 2019 A 69-year-old man started taking the dipeptidyl peptidase-4 inhibitor, vildagliptin. Vildagliptin 71-83 dipeptidyl peptidase 4 Homo sapiens 37-59 30172711-1 2018 The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin (VG) is used to treat type 2 diabetes. Vildagliptin 45-57 dipeptidyl peptidase 4 Homo sapiens 4-26 30172711-1 2018 The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin (VG) is used to treat type 2 diabetes. Vildagliptin 45-57 dipeptidyl peptidase 4 Homo sapiens 28-33 29498469-7 2018 CONCLUSION: Treatment with DPP-4 inhibition with vildagliptin results in 15% lower fasting and postprandial glucagon levels compared to SGLT-2 inhibition with dapagliflozin. Vildagliptin 49-61 dipeptidyl peptidase 4 Homo sapiens 27-32 29274348-5 2018 DPP4is were associated with an increased risk for development of BP (adjusted odds ratio, 2.64; 95% confidence interval, 1.19-5.85; P = .02), with vildagliptin showing the highest adjusted odds ratio (3.57 [95% confidence interval, 1.07-11.84; P = .04]). Vildagliptin 147-159 dipeptidyl peptidase 4 Homo sapiens 0-4 29274348-10 2018 CONCLUSIONS: DPP4is, especially vildagliptin, are associated with an increased risk for development of BP. Vildagliptin 32-44 dipeptidyl peptidase 4 Homo sapiens 13-17 29409972-4 2018 Notably, genetic ablation of DPP4 or treatment with a DPP4 inhibitor (vildagliptin) prevented HFD-induced HCC. Vildagliptin 70-82 dipeptidyl peptidase 4 Homo sapiens 54-58 29359260-8 2018 DPP-4 inhibitors have a controversial effect: saxagliptin and alogliptin may increase the risk of HF as opposed to vildagliptin and sitagliptin. Vildagliptin 115-127 dipeptidyl peptidase 4 Homo sapiens 0-5 29396374-2 2018 We implemented this phase II study to test the hypothesis that vildagliptin, a dipeptidyl peptidase-4 inhibitor, is superior to placebo in terms of reducing the risk of postpartum diabetes. Vildagliptin 63-75 dipeptidyl peptidase 4 Homo sapiens 79-101 28418203-1 2018 BACKGROUND: Vildagliptin is a dipeptidyl peptidase-4 inhibitor commonly used as a dual oral agent with metformin, thiazolidinediones, or sulfonylurea for the treatment of type 2 diabetes mellitus (T2DM). Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 30-52 28631242-1 2017 INTRODUCTION: To assess the impact of duration of type 2 diabetes on glucose-lowering effectiveness of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin versus sulfonylureas (SUs) in a real-life setting. Vildagliptin 148-160 dipeptidyl peptidase 4 Homo sapiens 107-129 29032139-1 2018 OBJECTIVES: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction. Vildagliptin 93-105 dipeptidyl peptidase 4 Homo sapiens 59-81 28983844-5 2017 This review will focus on vildagliptin, a DPP-4 inhibitor with a large body of evidence in patients with moderate to severe renal failure and a good clinical profile in terms of efficacy and safety. Vildagliptin 26-38 dipeptidyl peptidase 4 Homo sapiens 42-47 29632607-3 2017 Vildagliptin, one of the earliest DPP-4 inhibitors, has been tested across the entire spectrum of type 2 diabetes and has been in clinical use for 20 years. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 34-39 29632608-5 2017 The studies establish that vildagliptin is a selective DPP-4 inhibitor that blocks GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) inactivation, thereby prolonging their action, resulting in improved glycaemic control. Vildagliptin 27-39 dipeptidyl peptidase 4 Homo sapiens 55-60 29632609-0 2017 Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes. Vildagliptin 82-94 dipeptidyl peptidase 4 Homo sapiens 0-22 29632609-8 2017 This review encompasses unique developments in the global landscape, and the role DPP-4 inhibitors, specifically vildagliptin, have played in research advancement and optimisation of diabetes care in a diverse population with T2DM worldwide. Vildagliptin 113-125 dipeptidyl peptidase 4 Homo sapiens 82-87 29632610-1 2017 Vildagliptin is one of the most extensively studied dipeptidyl peptidase-4 (DPP-4) inhibitors in terms of its clinical utility. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 52-74 29632610-1 2017 Vildagliptin is one of the most extensively studied dipeptidyl peptidase-4 (DPP-4) inhibitors in terms of its clinical utility. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 76-81 28631242-1 2017 INTRODUCTION: To assess the impact of duration of type 2 diabetes on glucose-lowering effectiveness of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin versus sulfonylureas (SUs) in a real-life setting. Vildagliptin 148-160 dipeptidyl peptidase 4 Homo sapiens 131-136 28403729-1 2017 INTRODUCTION: Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for the treatment of type 2 diabetes mellitus, combined or not with metformin. Vildagliptin 14-26 dipeptidyl peptidase 4 Homo sapiens 57-79 28489279-18 2017 We judged none of the included trials at low risk of bias for all "Risk of bias" domains and did not perform meta-analyses because there were not enough trials.One trial comparing the DPP-4 inhibitor vildagliptin with placebo reported no deaths (very low-quality evidence). Vildagliptin 200-212 dipeptidyl peptidase 4 Homo sapiens 184-189 28367418-3 2017 To understand such micro-environment, we performed in silico interaction analysis between a human target protein, Dipeptidyl Peptidase-IV (DPP-4), and three anti-diabetic drugs (saxagliptin, linagliptin and vildagliptin). Vildagliptin 207-219 dipeptidyl peptidase 4 Homo sapiens 114-137 27895112-1 2017 The main route of elimination of vildagliptin, which is an inhibitor of dipeptidyl peptidase-4 (DPP-4), in humans is cyano group hydrolysis to produce a carboxylic acid metabolite M20.7. Vildagliptin 33-45 dipeptidyl peptidase 4 Homo sapiens 72-94 28182722-9 2017 Improvements in glycemic control were statistically significantly associated with the tested DPP-4 inhibitors in the high HGI group (-2.4, -1.4, -1.2 and -2.2% [-26.2, -15.3, -13.1 and -24.0 mmol/mol] for vildagliptin, linagliptin, saxagliptin and sitagliptin, respectively) but not in the low HGI group. Vildagliptin 205-217 dipeptidyl peptidase 4 Homo sapiens 93-98 28408838-10 2017 Further, it can be speculated that glucagon suppression may become the predominant mechanism via which glycemic control is improved when treatment with a DPP-4 inhibitor, such as vildagliptin, is initiated late in the natural course of T2DM. Vildagliptin 179-191 dipeptidyl peptidase 4 Homo sapiens 154-159 27939504-4 2017 Donor lungs were preconditioned with saline or the CD26/DPP4 inhibitor vildagliptin (1 mug/mL [3 muM]). Vildagliptin 71-83 dipeptidyl peptidase 4 Homo sapiens 56-60 27895112-1 2017 The main route of elimination of vildagliptin, which is an inhibitor of dipeptidyl peptidase-4 (DPP-4), in humans is cyano group hydrolysis to produce a carboxylic acid metabolite M20.7. Vildagliptin 33-45 dipeptidyl peptidase 4 Homo sapiens 96-101 27321385-1 2016 The dipeptidyl peptidase-4 inhibitors vildagliptin and sitagliptin are effective in treating patients with type 2 diabetes mellitus. Vildagliptin 38-50 dipeptidyl peptidase 4 Homo sapiens 4-26 28093996-13 2017 Sitagliptin and vildagliptin are dipeptidyl peptidase-4 inhibitors and have no risk of hypoglycemia when used as monotherapy. Vildagliptin 16-28 dipeptidyl peptidase 4 Homo sapiens 33-55 27759084-7 2016 In HepG2 cells, vildagliptin, M20.7, and sitagliptin - another DPP-4 inhibitor - induced S100A9 mRNA. Vildagliptin 16-28 dipeptidyl peptidase 4 Homo sapiens 63-68 27598511-2 2016 OBJECTIVE: To evaluate the effects of the DPP-4 inhibitor, vildagliptin (VILD), during intraduodenal (ID) glucose infusion at 2 different rates within the physiological range of gastric emptying, in type 2 diabetes. Vildagliptin 59-71 dipeptidyl peptidase 4 Homo sapiens 42-47 27759084-1 2016 Vildagliptin is a potent, orally active inhibitor of dipeptidyl peptidase-4 (DPP-4) for the treatment of type 2 diabetes mellitus. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 53-75 27759084-1 2016 Vildagliptin is a potent, orally active inhibitor of dipeptidyl peptidase-4 (DPP-4) for the treatment of type 2 diabetes mellitus. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 77-82 27031194-10 2016 Disproportionality was also observed for each DPP-IV inhibitor: vildagliptin (ROR 225 3, 95% CI 148 9-340 9), sitagliptin (ROR 17 0, 95% CI 8 9-32 5) and saxagliptin (ROR 16 5, 95% CI 2 3-119 1). Vildagliptin 64-76 dipeptidyl peptidase 4 Homo sapiens 46-52 27520566-4 2016 Here we describe a patient who developed drug-induced acute lung injury shortly after the administration of the dipeptidyl peptidase-4 inhibitor vildagliptin. Vildagliptin 145-157 dipeptidyl peptidase 4 Homo sapiens 112-134 27520566-12 2016 The precise mechanism of her vildagliptin-induced lung injury remains uncertain, but physicians should consider that dipeptidyl peptidase-4 inhibitor-induced lung injury, although rare, may appear acutely, even within days after administration of this drug. Vildagliptin 29-41 dipeptidyl peptidase 4 Homo sapiens 117-139 27031194-14 2016 The signal was higher with vildagliptin than with the other DPP-IV inhibitors. Vildagliptin 27-39 dipeptidyl peptidase 4 Homo sapiens 60-66 27193434-1 2016 We conducted this pilot study to examine efficacy and safety of switching from subcutaneous injection of insulin to oral administration of a DPP-4 inhibitor, vildagliptin, in type 2 diabetic patients undergoing hemodialysis. Vildagliptin 158-170 dipeptidyl peptidase 4 Homo sapiens 141-146 27207543-0 2016 Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist. Vildagliptin 105-117 dipeptidyl peptidase 4 Homo sapiens 83-88 27207543-1 2016 We quantified the contribution of GLP-1 as a mediator of the therapeutic effects of dipeptidyl peptidase 4 (DPP-4) inhibition (vildagliptin) by using the GLP-1 receptor antagonist exendin [9-39] in patients with type 2 diabetes and in healthy subjects. Vildagliptin 127-139 dipeptidyl peptidase 4 Homo sapiens 84-106 27207543-1 2016 We quantified the contribution of GLP-1 as a mediator of the therapeutic effects of dipeptidyl peptidase 4 (DPP-4) inhibition (vildagliptin) by using the GLP-1 receptor antagonist exendin [9-39] in patients with type 2 diabetes and in healthy subjects. Vildagliptin 127-139 dipeptidyl peptidase 4 Homo sapiens 108-113 27376699-12 2016 Treatment intensification with second OAD, particularly with a DPP-4 inhibitor vildagliptin, resulted in good treatment response without tolerability issues despite delayed intensification of failing monotherapy across regions. Vildagliptin 79-91 dipeptidyl peptidase 4 Homo sapiens 63-68 27382546-1 2015 BACKGROUND: Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is wildly used to treat type 2 diabetes mellitus (T2DM) with mono- or combination-therapy. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 28-50 27382546-1 2015 BACKGROUND: Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is wildly used to treat type 2 diabetes mellitus (T2DM) with mono- or combination-therapy. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 52-57 26855580-0 2016 Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients? Vildagliptin 72-84 dipeptidyl peptidase 4 Homo sapiens 56-61 27209165-1 2016 Vildagliptin is an inhibitor of dipeptidyl peptidase-4 that is used for the treatment of type 2 diabetes mellitus. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 32-54 27067162-5 2016 In exploratory analysis, statistically significant ROR emerged for DPP-4-I as a class (ROR = 1.17; 95% CI = 1.05-1.29), saxagliptin (1.68; 1.29-2.17), vildagliptin (2.39; 1.38-4.14), and rosiglitazone (13.98; 13.30-14.70). Vildagliptin 151-163 dipeptidyl peptidase 4 Homo sapiens 67-72 26786576-2 2016 This study was designed to evaluate whether a protein preload could improve the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin to increase incretin concentrations, slow gastric emptying, and lower postprandial glycemia in type 2 diabetes. Vildagliptin 137-149 dipeptidyl peptidase 4 Homo sapiens 96-118 26786576-2 2016 This study was designed to evaluate whether a protein preload could improve the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin to increase incretin concentrations, slow gastric emptying, and lower postprandial glycemia in type 2 diabetes. Vildagliptin 137-149 dipeptidyl peptidase 4 Homo sapiens 120-125 26950829-1 2016 Objective The present study aimed to compare the effects of the dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin and saxagliptin on 24 hour acute glucose fluctuations in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with a combination of metformin and sulfonylurea. Vildagliptin 106-118 dipeptidyl peptidase 4 Homo sapiens 64-86 26950829-1 2016 Objective The present study aimed to compare the effects of the dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin and saxagliptin on 24 hour acute glucose fluctuations in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with a combination of metformin and sulfonylurea. Vildagliptin 106-118 dipeptidyl peptidase 4 Homo sapiens 88-93 26871938-1 2016 The enantiomers of vildagliptin, an orally available and selective dipeptidyl-peptidase-4 inhibitor used for the treatment of type II diabetes, have been separated by CD-modified CZE, using uncoated fused-silica capillary. Vildagliptin 19-31 dipeptidyl peptidase 4 Homo sapiens 67-89 26855580-2 2016 We aimed to compare the efficacy of the DPP-4 inhibitor vildagliptin (50 mg twice daily [bid]) between Japanese and Caucasian populations. Vildagliptin 56-68 dipeptidyl peptidase 4 Homo sapiens 40-45 27048342-11 2016 CONCLUSION: DPP-4 inhibitors cause a significant increase in plasma adiponectin concentrations and this effect is greater with vildagliptin than sitagliptin. Vildagliptin 127-139 dipeptidyl peptidase 4 Homo sapiens 12-17 26824365-7 2016 Dipeptidyl peptidase-IV inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) are not inferior to sulfonylureas, causing significantly less hypoglycaemia and not inducing weight gain. Vildagliptin 87-99 dipeptidyl peptidase 4 Homo sapiens 0-23 26301063-1 2015 OBJECTIVE: The present study aimed to assess the patient preference and tolerability of oral dipeptidyl peptidase-4 inhibitor (vildagliptin) versus injectable glucagon-like peptide-1 analog (liraglutide) in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Vildagliptin 127-139 dipeptidyl peptidase 4 Homo sapiens 93-115 26173919-2 2015 The eight available DPP-4 inhibitors, including alogliptin, anagliptin, gemigliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin, and vildagliptin, are small molecules used orally with identical mechanism of action and similar safety profiles in patients with T2DM. Vildagliptin 143-155 dipeptidyl peptidase 4 Homo sapiens 20-25 26316706-1 2015 BACKGROUND: The objective of this study was to assess the effects of metformin monotherapy or combined treatment with a dipeptidyl peptidase-4 inhibitor (vildagliptin) on apelin levels in patients with type 2 diabetes mellitus. Vildagliptin 154-166 dipeptidyl peptidase 4 Homo sapiens 120-142 27642611-9 2016 In conclusion DPP-4 inhibitors such as vildagliptin and sitagliptin may form a suitable glucose-lowering therapy option for Ramadan fasting patients. Vildagliptin 39-51 dipeptidyl peptidase 4 Homo sapiens 14-19 26603933-7 2015 3T3-L1 adipocytes were treated with the DPP-4 inhibitor vildagliptin (2 nM) or the GLP-1 mimetic exendin-4 (5 nM). Vildagliptin 56-68 dipeptidyl peptidase 4 Homo sapiens 40-45 26816911-2 2015 Inhibitors of DPP-4 enzyme like Sitagliptin and Vildagliptin have shown Anti-oxidant properties in many studies, both invivo and invitro. Vildagliptin 48-60 dipeptidyl peptidase 4 Homo sapiens 14-19 26312070-1 2015 BACKGROUND: Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes mellitus (T2DM), shows beneficial effects on endothelial function. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 28-33 26166078-3 2015 The central systolic blood pressure (SBP) has become more important than the brachial SBP in the assessment of cardiovascular risk.This case report describes the effect of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, on the central SBP in a 54-year-old woman with hypertension and DM. Vildagliptin 172-184 dipeptidyl peptidase 4 Homo sapiens 188-210 26166078-3 2015 The central systolic blood pressure (SBP) has become more important than the brachial SBP in the assessment of cardiovascular risk.This case report describes the effect of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, on the central SBP in a 54-year-old woman with hypertension and DM. Vildagliptin 172-184 dipeptidyl peptidase 4 Homo sapiens 212-217 26089691-5 2015 The DPP-4 class was modeled with a meta-analysis of HbA1c and weight change, pooling results from published trials of alogliptin, linagliptin, saxagliptin, sitagliptin, and vildagliptin. Vildagliptin 173-185 dipeptidyl peptidase 4 Homo sapiens 4-9 23665884-4 2015 Our objective was to evaluate, by means of retrospective analysis, the efficacy of once-daily metformin and vildagliptin (a DPP-4 inhibitor) in reducing blood glucose for patients on combination therapy. Vildagliptin 108-120 dipeptidyl peptidase 4 Homo sapiens 124-129 23665884-2 2015 Most guidelines recommend treatment with a DPP-4 inhibitor, vildagliptin, in addition to metformin in a twice-daily regimen. Vildagliptin 60-72 dipeptidyl peptidase 4 Homo sapiens 43-48 25597851-0 2015 Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver. Vildagliptin 64-76 dipeptidyl peptidase 4 Homo sapiens 0-22 25931826-3 2015 In addition to diabetes education and pre-Ramadan assessments, the physician should also consider use of DPP-4 inhibitors (such as vildagliptin) during Ramadan fasting to minimize the risk of hypoglycemia in type 2 diabetic subjects. Vildagliptin 131-143 dipeptidyl peptidase 4 Homo sapiens 105-110 25597851-2 2015 In the present study, we determined the contribution rate of dipeptidyl peptidase-4 (DPP-4) to the hydrolysis of vildagliptin in the liver. Vildagliptin 113-125 dipeptidyl peptidase 4 Homo sapiens 61-83 25597851-2 2015 In the present study, we determined the contribution rate of dipeptidyl peptidase-4 (DPP-4) to the hydrolysis of vildagliptin in the liver. Vildagliptin 113-125 dipeptidyl peptidase 4 Homo sapiens 85-90 25597851-8 2015 These findings indicate that DPP-4 is greatly involved in vildagliptin hydrolysis in the liver. Vildagliptin 58-70 dipeptidyl peptidase 4 Homo sapiens 29-34 25664602-15 2015 CONCLUSIONS: This study demonstrates that the dipeptidyl-peptidase-4 inhibitor vildagliptin brings about a clinically significant decrease in hepatic triglyceride levels during 6 months of therapy unrelated to change in body weight. Vildagliptin 79-91 dipeptidyl peptidase 4 Homo sapiens 46-68 25331711-4 2015 Most DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, alogliptin) are predominantly excreted by the kidneys. Vildagliptin 36-48 dipeptidyl peptidase 4 Homo sapiens 5-10 25687897-2 2015 DESIGN: A systematic review and meta-analysis of randomised controlled trials (RCTs) of DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, linagliptin and alogliptin) on HbA1c were conducted. Vildagliptin 106-118 dipeptidyl peptidase 4 Homo sapiens 88-93 25687897-8 2015 INTERVENTIONS: Any DPP-4 inhibitor (vildagliptin, sitagliptin, saxagliptin, linagliptin or alogliptin). Vildagliptin 36-48 dipeptidyl peptidase 4 Homo sapiens 19-24 25452780-2 2015 The aim of the present study was to examine the postprandial effects of the dipeptidyl peptidase-4 inhibitor vildagliptin and the alpha-glucosidase inhibitor voglibose on endothelial dysfunction and lipid profiles following a single administration. Vildagliptin 109-121 dipeptidyl peptidase 4 Homo sapiens 76-98 24939431-11 2014 Human islets treated with the DPP-4 inhibitor, vildagliptin, showed increased secretion of insulin and intact GLP-1. Vildagliptin 47-59 dipeptidyl peptidase 4 Homo sapiens 30-35 25429228-1 2014 BACKGROUND: In order to test the hypothesis that the degree of weight change with the dipeptidyl peptidase-4 inhibitor vildagliptin is dependent on the level of glycemic control at baseline, the weight changes from pooled monotherapy studies after 24 weeks of therapy with vildagliptin were assessed versus the fasting plasma glucose (FPG) levels at baseline. Vildagliptin 119-131 dipeptidyl peptidase 4 Homo sapiens 86-108 24612221-12 2014 CONCLUSIONS: Vildagliptin action to block GLP-1 and GIP inactivation by DPP-4 improves glucagon dynamics during hypoglycaemia, hyperglycaemia and food re-challenge. Vildagliptin 13-25 dipeptidyl peptidase 4 Homo sapiens 72-77 26587020-1 2015 The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. Vildagliptin 184-196 dipeptidyl peptidase 4 Homo sapiens 168-173 26517136-0 2015 Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin. Vildagliptin 235-247 dipeptidyl peptidase 4 Homo sapiens 87-110 25204760-0 2014 Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release. Vildagliptin 34-46 dipeptidyl peptidase 4 Homo sapiens 0-22 24977657-0 2014 The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair beta-cell dysfunction and insulin resistance. Vildagliptin 37-49 dipeptidyl peptidase 4 Homo sapiens 4-26 25597711-16 2014 Vildagliptin was the most used drug among DPP-4 inhibitors. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 42-47 25171159-2 2014 In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D. Vildagliptin 72-84 dipeptidyl peptidase 4 Homo sapiens 15-37 25411599-1 2014 AIMS/INTRODUCTION: To investigate the efficacy and safety of vildagliptin, a potent dipeptidyl peptidase-4 inhibitor, as add-on to nateglinide, compared with switching to vildagliptin in Japanese type 2 diabetes patients poorly controlled with nateglinide. Vildagliptin 61-73 dipeptidyl peptidase 4 Homo sapiens 84-106 24682379-2 2014 In this work we compared RCT and real-life data on the efficacy of the dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin or sulfonylureas when added to metformin. Vildagliptin 113-125 dipeptidyl peptidase 4 Homo sapiens 71-94 24682379-2 2014 In this work we compared RCT and real-life data on the efficacy of the dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin or sulfonylureas when added to metformin. Vildagliptin 113-125 dipeptidyl peptidase 4 Homo sapiens 96-101 24604395-1 2014 INTRODUCTION: The objective of this study was to evaluate the efficacy and safety of vildagliptin, a potent dipeptidyl peptidase-4 inhibitor, as an add-on to metformin in Japanese patients with type 2 diabetes mellitus (T2DM). Vildagliptin 85-97 dipeptidyl peptidase 4 Homo sapiens 108-130 24547938-0 2014 Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 16-38 24837407-0 2014 Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 17-22 24638989-1 2014 The dipeptidyl peptidase-4 inhibitor vildagliptin (Galvus ) is approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. Vildagliptin 37-49 dipeptidyl peptidase 4 Homo sapiens 4-26 24547938-1 2014 INTRODUCTION: Vildagliptin is a dipeptidyl peptidase-4 inhibitor targeting the incretin system to improve glycemic control in type 2 diabetes. Vildagliptin 14-26 dipeptidyl peptidase 4 Homo sapiens 32-54 24547938-4 2014 EXPERT OPINION: Vildagliptin is an effective and well-tolerated oral dipeptidyl peptidase-4 inhibitor. Vildagliptin 16-28 dipeptidyl peptidase 4 Homo sapiens 69-91 24640595-0 2014 Capillary zone electrophoresis for determination of vildagliptin (a DPP-4 inhibitor) in pharmaceutical formulation and comparative study with HPLC. Vildagliptin 52-64 dipeptidyl peptidase 4 Homo sapiens 68-73 24485397-4 2014 We therefore assessed whether treatment with the DPP-4 inhibitor vildagliptin affected cytokine production and T-cell differentiation. Vildagliptin 65-77 dipeptidyl peptidase 4 Homo sapiens 49-54 24627624-2 2014 We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Vildagliptin 68-80 dipeptidyl peptidase 4 Homo sapiens 84-106 24627624-2 2014 We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Vildagliptin 68-80 dipeptidyl peptidase 4 Homo sapiens 108-113 24802729-3 2014 The aim was to assess lymphocyte subpopulations initially and after 14 days of treatment with DPP-4 inhibitors sitagliptin, saxagliptin and vildagliptin. Vildagliptin 140-152 dipeptidyl peptidase 4 Homo sapiens 94-99 24279801-3 2014 We conducted a randomized, double-blind, placebo-controlled, phase II trial to assess safety and efficacy of the DPP-4 inhibitor vildagliptin. Vildagliptin 129-141 dipeptidyl peptidase 4 Homo sapiens 113-118 25671081-4 2013 In the current work, we first report the inhibition of the native activity of PI-PLC by two DPP4 inhibitors - vildagliptin (LAF-237) and K-579. Vildagliptin 110-122 dipeptidyl peptidase 4 Homo sapiens 92-96 24163113-0 2013 Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Vildagliptin 109-121 dipeptidyl peptidase 4 Homo sapiens 0-22 23990203-0 2013 Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study. Vildagliptin 179-191 dipeptidyl peptidase 4 Homo sapiens 145-167 23821355-3 2013 It was, therefore, of interest to assess the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor vildagliptin in patients with T2DM >=75 years who also have moderate or severe RI. Vildagliptin 111-123 dipeptidyl peptidase 4 Homo sapiens 78-100 24163113-1 2013 INTRODUCTION: Saxagliptin, sitagliptin, and vildagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors widely approved for use in patients with type 2 diabetes. Vildagliptin 44-56 dipeptidyl peptidase 4 Homo sapiens 61-83 24163113-1 2013 INTRODUCTION: Saxagliptin, sitagliptin, and vildagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors widely approved for use in patients with type 2 diabetes. Vildagliptin 44-56 dipeptidyl peptidase 4 Homo sapiens 85-90 23659561-1 2013 OBJECTIVE: To assess treatment adherence to dipeptidyl peptidase-4 inhibitor vildagliptin compared with sulphonylureas (SU) in Muslim patients with type 2 diabetes mellitus who were fasting during Ramadan in the UK. Vildagliptin 77-89 dipeptidyl peptidase 4 Homo sapiens 44-66 24068868-5 2013 The five available DPP-4 inhibitors, also known as "gliptins" (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin), are small molecules used orally with similar overall clinical efficacy and safety profiles in patients with type 2 diabetes. Vildagliptin 76-88 dipeptidyl peptidase 4 Homo sapiens 19-24 23707531-5 2013 Five different DPP-4 inhibitors, often called as "gliptins", namely sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin have been approved hitherto for clinical use. Vildagliptin 81-93 dipeptidyl peptidase 4 Homo sapiens 15-20 23488656-3 2013 Dipeptidyl peptidase-4 (DPP-4) inhibitors, vildagliptin and sitagliptin, are oral anti-diabetic drugs often prescribed in patients with cardiovascular disease. Vildagliptin 43-55 dipeptidyl peptidase 4 Homo sapiens 24-29 23848558-0 2013 Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Vildagliptin 39-51 dipeptidyl peptidase 4 Homo sapiens 55-60 23782587-1 2013 OBJECTIVE: To assess the extent of pharmacokinetic and pharmacodynamic interaction between vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4) enzyme, and voglibose, an alpha-glucosidase inhibitor widely prescribed in Japan, when coadministered in Japanese patients with Type 2 diabetes. Vildagliptin 91-103 dipeptidyl peptidase 4 Homo sapiens 141-164 23782587-1 2013 OBJECTIVE: To assess the extent of pharmacokinetic and pharmacodynamic interaction between vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4) enzyme, and voglibose, an alpha-glucosidase inhibitor widely prescribed in Japan, when coadministered in Japanese patients with Type 2 diabetes. Vildagliptin 91-103 dipeptidyl peptidase 4 Homo sapiens 166-171 23782587-5 2013 The percentage of DPP-4 inhibition by vildagliptin remained unchanged when vildagliptin was given alone or co-administered with voglibose; maximum inhibition was 98.3 +- 1.4% (mean +- SD) for vildagliptin alone and 97.4 +- 1.1% with co-administration. Vildagliptin 38-50 dipeptidyl peptidase 4 Homo sapiens 18-23 23501107-3 2013 We determined the co-crystal structure of vildagliptin with DPP-4 by X-ray crystallography and compared the binding modes of six launched inhibitors in DPP-4. Vildagliptin 42-54 dipeptidyl peptidase 4 Homo sapiens 60-65 23318959-5 2013 The basis for synergy was independent of vildagliptin"s primary action as an inhibitor of dipeptidyl peptidase (DPP) IV. Vildagliptin 41-53 dipeptidyl peptidase 4 Homo sapiens 90-119 23501107-3 2013 We determined the co-crystal structure of vildagliptin with DPP-4 by X-ray crystallography and compared the binding modes of six launched inhibitors in DPP-4. Vildagliptin 42-54 dipeptidyl peptidase 4 Homo sapiens 152-157 23650450-0 2013 Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Vildagliptin 101-113 dipeptidyl peptidase 4 Homo sapiens 74-79 24185376-6 2013 Vildagliptin, a potent inhibitor of DPPIV/CD26 efficiently inhibited the DPPIV/CD26-catalysed hydrolysis reaction. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 36-41 23711060-3 2013 Vildagliptin is a molecule from the group of DPP 4 inhibitors which is recently used in internal outpatient care. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 45-50 23323612-3 2013 CASE REPORT: We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP-4 inhibitor, alogliptin. Vildagliptin 61-73 dipeptidyl peptidase 4 Homo sapiens 112-117 23430354-2 2013 Vildagliptin is a novel dipeptidyl peptidase-4 inhibitor that is given either alone or in combination with oral hypoglycemic drugs, including metformin. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 24-46 22882290-0 2013 Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man. Vildagliptin 61-73 dipeptidyl peptidase 4 Homo sapiens 28-50 24185376-6 2013 Vildagliptin, a potent inhibitor of DPPIV/CD26 efficiently inhibited the DPPIV/CD26-catalysed hydrolysis reaction. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 42-46 24185376-6 2013 Vildagliptin, a potent inhibitor of DPPIV/CD26 efficiently inhibited the DPPIV/CD26-catalysed hydrolysis reaction. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 73-78 24185376-6 2013 Vildagliptin, a potent inhibitor of DPPIV/CD26 efficiently inhibited the DPPIV/CD26-catalysed hydrolysis reaction. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 79-83 23818788-1 2013 Vildagliptin is a selective and potent dipeptidyl peptidase-4 inhibitor that improves glycemic control by inhibiting the degradation of both endogenous glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 39-61 24137964-9 2013 CONCLUSION: The glucose-lowering efficiency of combination therapy with metformin + vildagliptin, a DPP-4 inhibitor, was comparable with that of a metformin + SU combination, but safer with respect to the risk of developing hypoglycemia. Vildagliptin 84-96 dipeptidyl peptidase 4 Homo sapiens 100-105 23431062-5 2013 The dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin has also been shown to protect from hypoglycemia by enhancing glucagon counterregulation. Vildagliptin 46-58 dipeptidyl peptidase 4 Homo sapiens 4-27 23431062-5 2013 The dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin has also been shown to protect from hypoglycemia by enhancing glucagon counterregulation. Vildagliptin 46-58 dipeptidyl peptidase 4 Homo sapiens 29-34 23565473-6 2012 This appears to be the first reported case of acute pancreatitis from India probably attributable to use of vildagliptin, thus raising the possibility that this rare reaction may be a class effect of the DPP-4 inhibitors. Vildagliptin 108-120 dipeptidyl peptidase 4 Homo sapiens 204-209 22736406-2 2012 This work, therefore, aimed to assess the impact of such factors on the efficacy of the DPP-4 inhibitor, vildagliptin, in add-on therapy to metformin. Vildagliptin 105-117 dipeptidyl peptidase 4 Homo sapiens 88-93 22690943-1 2012 AIM: Assess long-term safety and efficacy of the dipeptidlyl peptidase-4 (DPP-4) inhibitor vildagliptin in 369 patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment (RI). Vildagliptin 91-103 dipeptidyl peptidase 4 Homo sapiens 74-79 22736406-10 2012 CONCLUSION: Vildagliptin add-on therapy to metformin was efficacious independent of IR stage and BMI, as well as disease duration and duration of prior metformin use, indicating that, contrary to a not uncommon perception, more obese patients and patients with long-standing T2DM can benefit from treatment with the DPP-4 inhibitor, vildagliptin. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 316-321 23110260-3 2012 The DPP IV inhibitors saxagliptin, vildagliptin, linagliptin, alogliptin and sitagliptin function by inhibiting the enzyme DPP IV, which breaks down GLP-1 and GIP, and have had significant success. Vildagliptin 35-47 dipeptidyl peptidase 4 Homo sapiens 4-10 23110260-3 2012 The DPP IV inhibitors saxagliptin, vildagliptin, linagliptin, alogliptin and sitagliptin function by inhibiting the enzyme DPP IV, which breaks down GLP-1 and GIP, and have had significant success. Vildagliptin 35-47 dipeptidyl peptidase 4 Homo sapiens 123-129 22686547-2 2012 The aim of this review is to compare the clinical pharmacokinetics of available DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) for the purpose of identifying potential selection preferences according to individual patient variables and co-morbidities. Vildagliptin 152-164 dipeptidyl peptidase 4 Homo sapiens 80-85 22855332-1 2012 CONTEXT: The dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits glucagon secretion at hyperglycemia but appears to enhance glucagon counterregulation during hypoglycemia in type 2 diabetes. Vildagliptin 47-59 dipeptidyl peptidase 4 Homo sapiens 13-35 22672501-4 2012 DESIGN: We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes. Vildagliptin 99-111 dipeptidyl peptidase 4 Homo sapiens 60-82 22191695-2 2012 Vildagliptin is an oral DPP-4 inhibitor approved in more than 70 countries. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 24-29 22397507-4 2012 AREAS COVERED: This paper provides an overview of the clinical results of combination therapy with metformin and the DPP-4 inhibitor vildagliptin in T2DM patients. Vildagliptin 133-145 dipeptidyl peptidase 4 Homo sapiens 117-122 22456294-1 2012 OBJECTIVE: To assess the effects of meal timing on the pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin in Japanese patients with Type 2 diabetes. Vildagliptin 142-154 dipeptidyl peptidase 4 Homo sapiens 100-123 22051153-5 2012 Fifty-nine drug-naive patients with type 2 diabetes (T2D) were randomized to either 1 year treatment with the DPP-4 inhibitor vildagliptin (100 mg, once daily; n = 29) or placebo (n = 30). Vildagliptin 126-138 dipeptidyl peptidase 4 Homo sapiens 110-115 22390829-1 2012 Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Vildagliptin 61-73 dipeptidyl peptidase 4 Homo sapiens 28-50 22456294-1 2012 OBJECTIVE: To assess the effects of meal timing on the pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin in Japanese patients with Type 2 diabetes. Vildagliptin 142-154 dipeptidyl peptidase 4 Homo sapiens 125-130 22442825-11 2012 The present model can be used to predict the effects of other dosage regimens of vildagliptin on DPP-4 inhibition, active GLP-1, glucose and insulin concentrations, or can be modified and applied to other incretin-related anti-diabetes therapies. Vildagliptin 81-93 dipeptidyl peptidase 4 Homo sapiens 97-102 22442826-4 2012 RESULTS: A target-mediated drug disposition (TMDD) model accounting for capacity-limited high affinity binding of vildagliptin to DPP-4 in plasma and tissues had good predictive performance. Vildagliptin 114-126 dipeptidyl peptidase 4 Homo sapiens 130-135 22442826-5 2012 Modelling the full time course of the vildagliptin-DPP-4 interaction suggested parallel vildagliptin dissociation from DPP-4 by a slow first-order process and hydrolysis by DPP-4 to an inactive metabolite as a disposition mechanism. Vildagliptin 38-50 dipeptidyl peptidase 4 Homo sapiens 51-56 22442826-6 2012 Due to limited amounts of DPP-4, vildagliptin concentrations increased slightly more than dose proportionally. Vildagliptin 33-45 dipeptidyl peptidase 4 Homo sapiens 26-31 22442826-9 2012 CONCLUSIONS: Vildagliptin is both an inhibitor and substrate for DPP-4. Vildagliptin 13-25 dipeptidyl peptidase 4 Homo sapiens 65-70 22442826-10 2012 By utilizing the TMDD approach, slow dissociation of vildagliptin from DPP-4 was found in patients and the half-life of hydrolysis by DPP-4 estimated. Vildagliptin 53-65 dipeptidyl peptidase 4 Homo sapiens 71-76 22442826-10 2012 By utilizing the TMDD approach, slow dissociation of vildagliptin from DPP-4 was found in patients and the half-life of hydrolysis by DPP-4 estimated. Vildagliptin 53-65 dipeptidyl peptidase 4 Homo sapiens 134-139 21867423-5 2011 Dilution assay indicated a long dissociation half-life (730 min) relative to DPPIV inhibitor vildagliptin. Vildagliptin 93-105 dipeptidyl peptidase 4 Homo sapiens 77-82 22339447-1 2012 Vildagliptin is an orally active, potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, shown to be effective and well tolerated in patients with type 2 diabetes mellitus (T2DM) as either monotherapy or in combination with other anti-diabetic agents. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 55-77 22339447-1 2012 Vildagliptin is an orally active, potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, shown to be effective and well tolerated in patients with type 2 diabetes mellitus (T2DM) as either monotherapy or in combination with other anti-diabetic agents. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 79-84 22339447-9 2012 The DPP-4 enzyme contributes to the formation of the major hydrolysis metabolite, LAY151; therefore, vildagliptin is also a substrate of DPP-4. Vildagliptin 101-113 dipeptidyl peptidase 4 Homo sapiens 4-9 22339447-9 2012 The DPP-4 enzyme contributes to the formation of the major hydrolysis metabolite, LAY151; therefore, vildagliptin is also a substrate of DPP-4. Vildagliptin 101-113 dipeptidyl peptidase 4 Homo sapiens 137-142 22339447-19 2012 Oral administration of vildagliptin to patients with T2DM completely inhibits DPP-4 activity at a variety of doses. Vildagliptin 23-35 dipeptidyl peptidase 4 Homo sapiens 78-83 22339447-21 2012 Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 42-47 22339447-21 2012 Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 101-106 22339447-22 2012 Similar potency of DPP-4 inhibition by vildagliptin has been reported in different ethnic groups, indicating that ethnicity does not affect the pharmacodynamics of vildagliptin. Vildagliptin 39-51 dipeptidyl peptidase 4 Homo sapiens 19-24 22661900-1 2012 The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years" duration in various populations with type 2 diabetes mellitus. Vildagliptin 65-77 dipeptidyl peptidase 4 Homo sapiens 31-53 22616349-0 2011 Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes. Vildagliptin 33-45 dipeptidyl peptidase 4 Homo sapiens 17-22 21733061-1 2011 AIM: Assess safety/tolerability and efficacy of the DPP-4 inhibitor vildagliptin in 515 patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment (RI). Vildagliptin 68-80 dipeptidyl peptidase 4 Homo sapiens 52-57 21507182-0 2011 Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Vildagliptin 61-73 dipeptidyl peptidase 4 Homo sapiens 28-50 21507182-1 2011 Inhibition of dipeptidyl peptidase-4 (DPP-4) by vildagliptin prevents degradation of glucagon-like peptide-1 (GLP-1) and reduces glycaemia in patients with type 2 diabetes mellitus, with low risk for hypoglycaemia and no weight gain. Vildagliptin 48-60 dipeptidyl peptidase 4 Homo sapiens 14-36 21788633-1 2011 OBJECTIVE: To investigate whether the dipeptidyl peptidase-4 inhibitor vildagliptin improves endothelium-dependent vasodilatation in patients with type 2 diabetes. Vildagliptin 71-83 dipeptidyl peptidase 4 Homo sapiens 38-60 21507182-1 2011 Inhibition of dipeptidyl peptidase-4 (DPP-4) by vildagliptin prevents degradation of glucagon-like peptide-1 (GLP-1) and reduces glycaemia in patients with type 2 diabetes mellitus, with low risk for hypoglycaemia and no weight gain. Vildagliptin 48-60 dipeptidyl peptidase 4 Homo sapiens 38-43 21507182-2 2011 Vildagliptin binds covalently to the catalytic site of DPP-4, eliciting prolonged enzyme inhibition. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 55-60 21913883-1 2011 The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. Vildagliptin 85-97 dipeptidyl peptidase 4 Homo sapiens 4-26 21913883-1 2011 The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. Vildagliptin 85-97 dipeptidyl peptidase 4 Homo sapiens 28-33 21547496-2 2011 The dipeptidylpeptidase (DPP)-4 inhibitor vildagliptin improves beta cell function both acutely and chronically (up to 2 years). Vildagliptin 42-54 dipeptidyl peptidase 4 Homo sapiens 4-31 21819162-1 2011 BACKGROUND AND OBJECTIVE: Vildagliptin and sitagliptin are oral dipeptidyl peptidase 4 inhibitors approved in Japan for the treatment of type 2 diabetes mellitus when adequate glycaemic control is not achieved with diet, exercise or sulphonylureas. Vildagliptin 26-38 dipeptidyl peptidase 4 Homo sapiens 64-86 21679097-2 2011 Vildagliptin is a new DPP-4 inhibitor approved in many countries for the treatment of T2DM. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 22-27 22521013-4 2011 Vildagliptin is an inhibitor of oral DPP-4, the most studied of this new class. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 37-42 21324812-4 2011 This occurred 5 weeks after the commencement of vildagliptin, a dipeptidyl-peptidase 4 inhibitor, for the treatment of type 2 diabetes mellitus. Vildagliptin 48-60 dipeptidyl peptidase 4 Homo sapiens 64-86 21595278-2 2011 New DPP-4 inhibitors are expected to be available soon in addition to currently available DPP-4 inhibitors, sitagliptin, vildagliptin, and alogliptin. Vildagliptin 121-133 dipeptidyl peptidase 4 Homo sapiens 4-9 21755761-0 2011 Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. Vildagliptin 59-71 dipeptidyl peptidase 4 Homo sapiens 17-40 21755761-0 2011 Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. Vildagliptin 59-71 dipeptidyl peptidase 4 Homo sapiens 42-47 21755761-8 2011 Vildagliptin is a drug from a new class of medications called dipeptidyl peptidase IV (DPP4) inhibitors. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 62-85 21755761-8 2011 Vildagliptin is a drug from a new class of medications called dipeptidyl peptidase IV (DPP4) inhibitors. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 87-91 21755761-9 2011 By inhibiting DPP-4, vildagliptin causes an increase in GLP-1, an intestinal hormone that aids in glucose homeostasis and insulin secretion. Vildagliptin 21-33 dipeptidyl peptidase 4 Homo sapiens 14-19 21755761-10 2011 Vildagliptin has a half-life of about 90 minutes; however, > or = 50% of DPP4 inhibition continues for more than 10 hours, allowing for once- or twice-daily dosing. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 76-80 21332170-4 2011 Vildagliptin, a specific inhibitor of DPPIV/CD26, was able to completely block the hydrolysis of the prodrugs in the presence of purified DPPIV/CD26 human, murine, and bovine serum. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 38-43 21332170-4 2011 Vildagliptin, a specific inhibitor of DPPIV/CD26, was able to completely block the hydrolysis of the prodrugs in the presence of purified DPPIV/CD26 human, murine, and bovine serum. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 44-48 21332170-4 2011 Vildagliptin, a specific inhibitor of DPPIV/CD26, was able to completely block the hydrolysis of the prodrugs in the presence of purified DPPIV/CD26 human, murine, and bovine serum. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 138-143 21332170-4 2011 Vildagliptin, a specific inhibitor of DPPIV/CD26, was able to completely block the hydrolysis of the prodrugs in the presence of purified DPPIV/CD26 human, murine, and bovine serum. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 144-148 21205107-3 2011 Therefore, individual gliptins need to be characterized and here we discuss the extensively studied DPP-4 inhibitor vildagliptin, which has binding characteristics that ensure inhibition of the enzyme beyond the presence of detectable drug levels in plasma. Vildagliptin 116-128 dipeptidyl peptidase 4 Homo sapiens 100-105 30290444-4 2011 DPP-4 inhibitors have a low incidence of hypoglycemia without significant weight gain and there is strong evidence that the administration of vildagliptin results in improved alpha- and beta-cell function. Vildagliptin 142-154 dipeptidyl peptidase 4 Homo sapiens 0-5 21727749-4 2011 The incritin memetics are potentially safe during Ramadan; the DPP4 inhibitors vildagliptin and sitagliptin provide an effective and safe therapeutic option, administered either alone or in combination with metformin or sulfonylureas. Vildagliptin 79-91 dipeptidyl peptidase 4 Homo sapiens 63-67 21609207-0 2011 Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers. Vildagliptin 36-48 dipeptidyl peptidase 4 Homo sapiens 52-75 21609207-1 2011 OBJECTIVE: This randomized, double-blind study evaluated the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor for treating type 2 diabetes, on cardiac repolarization and conduction. Vildagliptin 72-84 dipeptidyl peptidase 4 Homo sapiens 88-111 22127800-6 2011 The dipeptidyl peptidase-4 inhibitor, vildagliptin, is a good treatment option to minimize the risk of hypoglycemia over time, while maintaining good glucose control. Vildagliptin 38-50 dipeptidyl peptidase 4 Homo sapiens 4-26 21239518-0 2011 Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. Vildagliptin 25-37 dipeptidyl peptidase 4 Homo sapiens 14-19 21239518-2 2011 The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes. Vildagliptin 119-131 dipeptidyl peptidase 4 Homo sapiens 103-108 21488586-2 2011 Sitagliptin and vildagliptin are dipeptidyl peptidase 4 (DPP-4) inhibitors, also known as "gliptins". Vildagliptin 16-28 dipeptidyl peptidase 4 Homo sapiens 33-55 21488586-2 2011 Sitagliptin and vildagliptin are dipeptidyl peptidase 4 (DPP-4) inhibitors, also known as "gliptins". Vildagliptin 16-28 dipeptidyl peptidase 4 Homo sapiens 57-62 21921362-0 2011 The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Vildagliptin 45-57 dipeptidyl peptidase 4 Homo sapiens 4-26 21921362-0 2011 The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Vildagliptin 45-57 dipeptidyl peptidase 4 Homo sapiens 28-33 21921362-1 2011 The potent and selective dipeptidyl peptidase-4 inhibitor vildagliptin improves glycemic control in patients with type 2 diabetes through incretin hormone-mediated increases in both alpha- and beta-cell responsiveness to glucose. Vildagliptin 58-70 dipeptidyl peptidase 4 Homo sapiens 25-47 20938933-3 2010 Many DPP4 inhibitors, such as sitagliptin and vildagliptin, have been developed and marketed, but superior therapeutic agents are still required. Vildagliptin 46-58 dipeptidyl peptidase 4 Homo sapiens 5-9 21966329-9 2011 These DPP-4 inhibitors include sitagliptin, saxagliptin, vildagliptin and many others which are still in the experimental phase. Vildagliptin 57-69 dipeptidyl peptidase 4 Homo sapiens 6-11 21079371-0 2010 [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin]. Vildagliptin 75-87 dipeptidyl peptidase 4 Homo sapiens 42-64 20964454-1 2010 Vildagliptin (Galvus , Jalra , Xiliarx ) is an orally administered dipeptidyl peptidase-4 (DPP-4) inhibitor. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 67-89 20964454-1 2010 Vildagliptin (Galvus , Jalra , Xiliarx ) is an orally administered dipeptidyl peptidase-4 (DPP-4) inhibitor. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 91-96 20708812-3 2010 Currently, three DPP-4 inhibitors - sitagliptin, vildagliptin and saxagliptin - have been approved in various countries worldwide. Vildagliptin 49-61 dipeptidyl peptidase 4 Homo sapiens 17-22 20925938-4 2010 Vildagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor that improves pancreatic islet function by enhancing both alpha- and beta-cell responsiveness to increased blood glucose. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 24-46 20925938-4 2010 Vildagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor that improves pancreatic islet function by enhancing both alpha- and beta-cell responsiveness to increased blood glucose. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 48-53 20707611-3 2010 DPP IV inhibitors (sitagliptin, vildagliptin, saxagliptin) offer new options for combined pharmacological therapy. Vildagliptin 32-44 dipeptidyl peptidase 4 Homo sapiens 0-6 20537746-1 2010 AIM: To investigate the efficacy and tolerability of vildagliptin, a potent and selective dipeptidyl peptidase-4 inhibitor, as add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus (T2DM) who were inadequately controlled. Vildagliptin 53-65 dipeptidyl peptidase 4 Homo sapiens 90-112 20860912-1 2010 OBJECTIVE: To assess the pharmacokinetics, pharmacodynamics and safety of vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4), in Japanese patients with Type 2 diabetes. Vildagliptin 74-86 dipeptidyl peptidase 4 Homo sapiens 124-147 20860912-1 2010 OBJECTIVE: To assess the pharmacokinetics, pharmacodynamics and safety of vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4), in Japanese patients with Type 2 diabetes. Vildagliptin 74-86 dipeptidyl peptidase 4 Homo sapiens 149-154 20860912-5 2010 DPP-4 activity was completely inhibited for varying durations by all doses of vildagliptin; the duration of complete DPP-4 inhibition was dose-dependent. Vildagliptin 78-90 dipeptidyl peptidase 4 Homo sapiens 0-5 20860912-6 2010 DPP-4 inhibition after vildagliptin 50 mg twice daily remained > 80% throughout the 24-h period. Vildagliptin 23-35 dipeptidyl peptidase 4 Homo sapiens 0-5 20642545-0 2010 Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes. Vildagliptin 101-113 dipeptidyl peptidase 4 Homo sapiens 67-90 21205499-7 2010 Three inhibitors of DPP4: sitagliptin, and vildagliptin and saxagliptin produce a prolonged inhibition of DPP4 and as a consequence increased effect of native incretins with better control of fasting and postprandial glucose and improve on A1c with a very few hypoglycemic events. Vildagliptin 43-55 dipeptidyl peptidase 4 Homo sapiens 20-24 21205499-7 2010 Three inhibitors of DPP4: sitagliptin, and vildagliptin and saxagliptin produce a prolonged inhibition of DPP4 and as a consequence increased effect of native incretins with better control of fasting and postprandial glucose and improve on A1c with a very few hypoglycemic events. Vildagliptin 43-55 dipeptidyl peptidase 4 Homo sapiens 106-110 20730070-6 2010 Dipeptidyl peptidase (DPP)-4 inhibitors are generally weight-neutral, although modest weight loss has been observed with the DPP-4 inhibitor, vildagliptin, in patients with relatively low baseline glycemia. Vildagliptin 142-154 dipeptidyl peptidase 4 Homo sapiens 0-28 20730070-6 2010 Dipeptidyl peptidase (DPP)-4 inhibitors are generally weight-neutral, although modest weight loss has been observed with the DPP-4 inhibitor, vildagliptin, in patients with relatively low baseline glycemia. Vildagliptin 142-154 dipeptidyl peptidase 4 Homo sapiens 125-130 20642545-1 2010 WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Vildagliptin is an orally active, potent inhibitor of dipeptidyl peptidase IV and was developed for the treatment of type 2 diabetes. Vildagliptin 42-54 dipeptidyl peptidase 4 Homo sapiens 96-119 20642545-6 2010 AIM: This randomized, double-blind, crossover study compared post-prandial hormonal and metabolic effects of vildagliptin, (an oral, potent, selective inhibitor of dipeptidyl peptidase IV [DPP-4]) administered morning or evening in patients with type 2 diabetes. Vildagliptin 109-121 dipeptidyl peptidase 4 Homo sapiens 164-187 20642545-6 2010 AIM: This randomized, double-blind, crossover study compared post-prandial hormonal and metabolic effects of vildagliptin, (an oral, potent, selective inhibitor of dipeptidyl peptidase IV [DPP-4]) administered morning or evening in patients with type 2 diabetes. Vildagliptin 109-121 dipeptidyl peptidase 4 Homo sapiens 189-194 20642545-9 2010 RESULTS: Vildagliptin inhibited DPP-4 activity (>80% for 15.5 h post-dose), and increased active glucagon-like peptide-1 compared with placebo. Vildagliptin 9-21 dipeptidyl peptidase 4 Homo sapiens 32-37 20298625-6 2010 According to these studies, the DPP-4 inhibitors sitagliptin and vildagliptin gave a mean HbA1c reduction of 0.7% and 0.6% respectively. Vildagliptin 65-77 dipeptidyl peptidase 4 Homo sapiens 32-37 19238312-4 2010 ASP4000 was found to inhibit human recombinant DPP4 activity with a K(i) of 1.05 nM, a k(on) value of 22.3 x 10(5) M(-1) s(-1), and a k (off) of 2.35 x 10(-3) M(-1) s(-1), with higher affinity than that of vildagliptin. Vildagliptin 206-218 dipeptidyl peptidase 4 Homo sapiens 47-51 20000418-4 2010 Vildagliptin, a specific inhibitor of DPPIV/CD26, was able to completely block the hydrolysis of the prodrugs in the presence of purified CD26 but also in human and bovine serum. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 38-43 20000418-4 2010 Vildagliptin, a specific inhibitor of DPPIV/CD26, was able to completely block the hydrolysis of the prodrugs in the presence of purified CD26 but also in human and bovine serum. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 44-48 20000418-4 2010 Vildagliptin, a specific inhibitor of DPPIV/CD26, was able to completely block the hydrolysis of the prodrugs in the presence of purified CD26 but also in human and bovine serum. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 138-142 20441397-3 2010 The objective of this review is to provide an overview of the challenges in managing T2DM in the elderly, with an emphasis on prevention of hypoglycaemia and the role of the DPP-4 inhibitor vildagliptin in this patient population. Vildagliptin 190-202 dipeptidyl peptidase 4 Homo sapiens 174-179 20441397-8 2010 Data on the DPP-4 inhibitor vildagliptin indicate that reductions in A1C in elderly patients are at least as good as those observed in younger patients and are achieved with minimal risk of hypoglycaemia. Vildagliptin 28-40 dipeptidyl peptidase 4 Homo sapiens 12-17 20518804-1 2010 AIM: To assess the cardiovascular and cerebrovascular (CCV) safety of the dipeptidyl peptidase-IV inhibitor vildagliptin. Vildagliptin 108-120 dipeptidyl peptidase 4 Homo sapiens 74-97 20067974-1 2010 OBJECTIVE: To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits glucagon levels than the sulfonylurea glimepiride during a meal. Vildagliptin 64-76 dipeptidyl peptidase 4 Homo sapiens 31-53 20380648-8 2010 The glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide and the dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin and vildagliptin effectively lower HbA1c; exenatide and liraglutide reduce weight and blood pressure and improve lipid profiles. Vildagliptin 146-158 dipeptidyl peptidase 4 Homo sapiens 88-110 19874253-1 2009 Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus (T2DM). Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 41-47 19755410-9 2009 Comparison of in vitro inhibition of DPP-IV by nateglinide and vildagliptin revealed IC(50) values of 17.1 and 2.1 microM respectively. Vildagliptin 63-75 dipeptidyl peptidase 4 Homo sapiens 37-43 19705345-0 2009 Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Vildagliptin 59-71 dipeptidyl peptidase 4 Homo sapiens 43-48 19385979-1 2009 Vildagliptin is an oral incretin enhancer that acts to increase active levels of the incretin hormone glucagon-like peptide-1 (GLP-1) by inhibiting the dipeptidyl peptidase-4 enzyme responsible for the rapid deactivation of GLP-1 in vivo. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 152-174 19545590-9 2009 In addition to incretin mimetics incretin enhancers which inhibit/delay degradation of incretins were developed: so-called DPP-4 inhibitors such as sitagliptin and vildagliptin are approved in Europe. Vildagliptin 164-176 dipeptidyl peptidase 4 Homo sapiens 123-128 19748065-2 2009 The first available DPP-4 inhibitors are sitagliptin and vildagliptin. Vildagliptin 57-69 dipeptidyl peptidase 4 Homo sapiens 20-25 19364302-2 2009 Vildagliptin, an orally active, potent and selective dipeptidyl peptidase IV (DPP-4) inhibitor, may represent an appropriate antihyperglycemic agent for combination with metformin to improve glycemic control in such patients. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 53-76 19364302-2 2009 Vildagliptin, an orally active, potent and selective dipeptidyl peptidase IV (DPP-4) inhibitor, may represent an appropriate antihyperglycemic agent for combination with metformin to improve glycemic control in such patients. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 78-83 19780719-3 2009 DPP-4 inhibitors (alogliptin, saxagliptin, sitagliptin and vildagliptin) correct the GLP-1 deficiency by blocking this degradation, prolonging the incretin effect and enhancing glucose homoeostasis. Vildagliptin 59-71 dipeptidyl peptidase 4 Homo sapiens 0-5 19581505-3 2009 This study tested the hypothesis that DPP-IV inhibition affects risk of clinical angioedema, by comparing the incidence of angioedema in patients treated with the DPP-IV inhibitor vildagliptin versus those treated with comparator in Phase III randomized clinical trials. Vildagliptin 180-192 dipeptidyl peptidase 4 Homo sapiens 38-44 19581505-3 2009 This study tested the hypothesis that DPP-IV inhibition affects risk of clinical angioedema, by comparing the incidence of angioedema in patients treated with the DPP-IV inhibitor vildagliptin versus those treated with comparator in Phase III randomized clinical trials. Vildagliptin 180-192 dipeptidyl peptidase 4 Homo sapiens 163-169 21437121-0 2009 Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes. Vildagliptin 83-95 dipeptidyl peptidase 4 Homo sapiens 14-36 21437121-7 2009 The pharmacology, efficacy and safety of vildagliptin, a novel DPP-4 inhibitor, are also discussed. Vildagliptin 41-53 dipeptidyl peptidase 4 Homo sapiens 63-68 19385980-1 2009 Vildagliptin is a potent and selective oral dipeptidyl peptidase-4 inhibitor that improves glycaemic control in patients with type 2 diabetes mellitus (T2DM) by increasing both alpha- and beta-cell responsiveness to glucose. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 44-66 19275548-6 2009 The other group comprises the gliptins (e.g. sitagliptin and vildagliptin) which boost endogenous incretin activity by inhibiting the enzyme dipeptidyl peptidase 4 (DPP 4) that degrades both GLP-1 and GIP. Vildagliptin 61-73 dipeptidyl peptidase 4 Homo sapiens 141-163 19418936-1 2009 Vildagliptin (Galvus) is a selective inhibitor of dipeptidylpeptidase-4, an enzyme involved in the metabolism of glucagon-like peptide-1 (GLP-1) secreted by L cells of the intestine. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 50-71 19288260-2 2009 By inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme, vildagliptin raises the levels of the active incretin hormones, glucagon-like peptide 1 and glucose-dependent insulinotropic peptide. Vildagliptin 57-69 dipeptidyl peptidase 4 Homo sapiens 18-40 19288260-2 2009 By inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme, vildagliptin raises the levels of the active incretin hormones, glucagon-like peptide 1 and glucose-dependent insulinotropic peptide. Vildagliptin 57-69 dipeptidyl peptidase 4 Homo sapiens 42-47 19174497-3 2009 OBJECTIVE: The aim of the study was to assess effects of the dipeptidyl peptidase-4 inhibitor vildagliptin on alpha-cell response to hyper- and hypoglycemia. Vildagliptin 94-106 dipeptidyl peptidase 4 Homo sapiens 61-83 19330494-6 2009 These can mainly be divided into two broad categories; GLP-1 agonists/analogs (exenatide, liraglutide), and dipeptidyl peptidase-4 (DPP-4; the enzyme responsible for rapid inactivation of incretins) inhibitors (sitagliptin, vildagliptin). Vildagliptin 224-236 dipeptidyl peptidase 4 Homo sapiens 108-130 19330494-6 2009 These can mainly be divided into two broad categories; GLP-1 agonists/analogs (exenatide, liraglutide), and dipeptidyl peptidase-4 (DPP-4; the enzyme responsible for rapid inactivation of incretins) inhibitors (sitagliptin, vildagliptin). Vildagliptin 224-236 dipeptidyl peptidase 4 Homo sapiens 132-137 19088168-3 2009 OBJECTIVE: We tested the hypothesis that DPP-4 inhibition with vildagliptin elicits changes in adipose tissue and skeletal muscle metabolism. Vildagliptin 63-75 dipeptidyl peptidase 4 Homo sapiens 41-46 19088168-6 2009 INTERVENTION: INTERVENTION included 7 d treatment with the selective DPP-4 inhibitor vildagliptin or placebo and a standardized test meal on d 7. Vildagliptin 85-97 dipeptidyl peptidase 4 Homo sapiens 69-74 19275548-6 2009 The other group comprises the gliptins (e.g. sitagliptin and vildagliptin) which boost endogenous incretin activity by inhibiting the enzyme dipeptidyl peptidase 4 (DPP 4) that degrades both GLP-1 and GIP. Vildagliptin 61-73 dipeptidyl peptidase 4 Homo sapiens 165-170 18931099-0 2009 Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Vildagliptin 37-49 dipeptidyl peptidase 4 Homo sapiens 0-22 18971371-8 2009 The effects on HbA1c and GLP-1 were superior to the short-acting DPP-4 inhibitor vildagliptin, demonstrating the potential of BI 1356 as a once daily treatment for type 2 diabetes at low therapeutic doses. Vildagliptin 81-93 dipeptidyl peptidase 4 Homo sapiens 65-70 19149538-3 2009 Various classes of structurally different DPP IV inhibitors are currently being explored and few of them such as Sitagliptin and Vildagliptin were successfully launched. Vildagliptin 129-141 dipeptidyl peptidase 4 Homo sapiens 42-48 18755155-1 2008 With vildagliptin and sitagliptin on the market for the treatment of type 2 diabetes, dipeptidyl peptidase 4 (DPP4, EC 3.4.14.5) research has entered a new era. Vildagliptin 5-17 dipeptidyl peptidase 4 Homo sapiens 110-114 19179813-6 2009 In addition to reducing HbA1c and fasting plasma glucose, the recently developed diabetes therapies GLP-1 receptor agonists (eg, exenatide, liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (eg, sitagliptin, vildagliptin) appear to have beneficial effects on beta-cell dysfunction and, possibly, on alpha-cell dysregulation. Vildagliptin 217-229 dipeptidyl peptidase 4 Homo sapiens 181-186 18957505-0 2009 Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. Vildagliptin 52-64 dipeptidyl peptidase 4 Homo sapiens 19-41 18832295-1 2009 Vildagliptin is an orally effective, potent, and selective inhibitor of dipeptidyl peptidase IV (DPP-4) that improves glycemic control in patients with type 2 diabetes. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 72-95 18832295-1 2009 Vildagliptin is an orally effective, potent, and selective inhibitor of dipeptidyl peptidase IV (DPP-4) that improves glycemic control in patients with type 2 diabetes. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 97-102 18832295-7 2009 Administration of vildagliptin 25 to 200 mg led to rapid and near-complete (>95%) inhibition of DPP-4 activity for at least 4 hours after dosing, which was associated with increases in plasma active glucagon-like peptide-1 of up to 2- to 3-fold compared with placebo. Vildagliptin 18-30 dipeptidyl peptidase 4 Homo sapiens 99-104 18832295-12 2009 Vildagliptin demonstrates potent inhibition of DPP-4 activity with excellent tolerability at doses of up to and including 200 mg qd. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 47-52 19022515-2 2008 The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Vildagliptin 103-115 dipeptidyl peptidase 4 Homo sapiens 69-74 18755155-3 2008 During the pre-clinical and clinical evaluation of vildagliptin and sitagliptin, there has been a growing awareness of the presence of other DPP4-like peptidases in various cells and tissues. Vildagliptin 51-63 dipeptidyl peptidase 4 Homo sapiens 141-145 18929237-8 2008 The authors conducted a literature search of various databases to identify the clinical trials involving the DPP inhibitors and concluded that the DPP-4 inhibitors, for example, sitagliptin and vildagliptin, are efficacious for managing diabetes as monotherapy or combination therapy. Vildagliptin 194-206 dipeptidyl peptidase 4 Homo sapiens 147-152 18284434-2 2008 METHODS: This 24-week, multicentre, randomized, double-blind, placebo-controlled study assessed the effects of the dipeptidyl peptidase-4 inhibitor vildagliptin (50 mg given once or twice daily) vs. placebo added to glimepiride (4 mg once daily) in 515 patients with T2DM. Vildagliptin 148-160 dipeptidyl peptidase 4 Homo sapiens 115-137 18422675-2 2008 RESEARCH DESIGN AND METHODS: The relative selectivity of the DPP-4 inhibitor, vildagliptin, was determined by comparing its K(I) (concentration of compound yielding 50% inhibition of the enzyme) values for inhibition of recombinant human DPP-4, DPP-8 and DPP-9 assessed in vitro. Vildagliptin 78-90 dipeptidyl peptidase 4 Homo sapiens 61-66 18422675-2 2008 RESEARCH DESIGN AND METHODS: The relative selectivity of the DPP-4 inhibitor, vildagliptin, was determined by comparing its K(I) (concentration of compound yielding 50% inhibition of the enzyme) values for inhibition of recombinant human DPP-4, DPP-8 and DPP-9 assessed in vitro. Vildagliptin 78-90 dipeptidyl peptidase 4 Homo sapiens 238-243 18628530-4 2008 Liraglutide (GLP-1 mimetic) and vildagliptin (DPP 4 inhibitor) are expected to arrive on the market soon. Vildagliptin 32-44 dipeptidyl peptidase 4 Homo sapiens 46-51 18769687-7 2008 The second class, the dipeptidyl peptidase-4 inhibitors (such as sitagliptin and vildagliptin) rely on production of endogenous GLP-1 and act by reducing its turnover. Vildagliptin 81-93 dipeptidyl peptidase 4 Homo sapiens 22-44 19017837-3 2008 In the last 5 years new glucose lowering drugs acting on novel pathways have been developed, licensed and launched, such as the glucagon-like peptide (GLP-1) agonists (exenatide) and dipeptidyl peptidase (DPP-IV) inhibitors such as sitagliptin and vildagliptin. Vildagliptin 248-260 dipeptidyl peptidase 4 Homo sapiens 205-211 18577160-4 2008 A number of new therapeutic agents are undergoing clinical development, including glucagon-like peptide 1 mimetics (exenatide and liraglutide) and dipeptidyl peptidase 4 inhibitors (sitagliptin and vildagliptin), which target the incretin system, and the cannabinoid-1 receptor antagonists (rimonabant), which target the endocannabinoid system, may hold some promise for meeting these unmet needs. Vildagliptin 198-210 dipeptidyl peptidase 4 Homo sapiens 147-169 18542012-5 2008 The orally available dipeptidyl peptidase-4 inhibitors, that is sitagliptin and vildagliptin reduce haemoglobin A1c by 0.5-1.0%, are weight neutral and without gastrointestinal side-effects. Vildagliptin 80-92 dipeptidyl peptidase 4 Homo sapiens 21-43 18471347-1 2008 OBJECTIVE: Vildagliptin is an orally active, potent and selective DPP-4 inhibitor that improves glycemic control in patients with type 2 diabetes by increasing alpha- and beta-cell responsiveness to glucose. Vildagliptin 11-23 dipeptidyl peptidase 4 Homo sapiens 66-71 18795210-11 2008 DPP-4 inhibitors such as sitagliptin and vildagliptin result in clinically significant reductions in HbA1c, and are weight neutral with few GI side effects. Vildagliptin 41-53 dipeptidyl peptidase 4 Homo sapiens 0-5 18793589-0 2008 Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. Vildagliptin 108-120 dipeptidyl peptidase 4 Homo sapiens 74-97 18793589-1 2008 BACKGROUND: Vildagliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4) that improves glycemic control and pancreatic b-cell function in patients with Type 2 diabetes. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 53-76 18793589-1 2008 BACKGROUND: Vildagliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4) that improves glycemic control and pancreatic b-cell function in patients with Type 2 diabetes. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 78-83 20694081-2 2008 Vildagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4), a new class of oral antidiabetic agents. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 32-54 20694081-2 2008 Vildagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4), a new class of oral antidiabetic agents. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 56-61 18269436-1 2008 Vildagliptin is a potent, selective and reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for rapid inactivation of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 64-86 18425967-2 2008 One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin and vildagliptin. Vildagliptin 139-151 dipeptidyl peptidase 4 Homo sapiens 76-98 18425967-2 2008 One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin and vildagliptin. Vildagliptin 139-151 dipeptidyl peptidase 4 Homo sapiens 100-105 18425967-18 2008 All published randomised controlled trials of at least 12 weeks treatment with sitagliptin and vildagliptin only reported routine laboratory safety measurements AUTHORS" CONCLUSIONS: DPP-4 inhibitors have some theoretical advantages over existing therapies with oral antidiabetic compounds but should currently be restricted to individual patients. Vildagliptin 95-107 dipeptidyl peptidase 4 Homo sapiens 183-188 17961192-2 2008 Vildagliptin is a new, potent, and selective inhibitor of DPP-4. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 58-63 18341596-1 2008 AIMS: To compare the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor, vildagliptin, with the alpha glucosidase inhibitor, acarbose, in drug-naive patients with Type 2 diabetes. Vildagliptin 88-100 dipeptidyl peptidase 4 Homo sapiens 54-76 18269436-4 2008 Mechanistic studies of vildagliptin performed to characterise the effects of DPP-4 inhibition on pancreatic islet function and glucose metabolism have found that vildagliptin produces dose-dependent reductions in DPP-4; these result in persistent levels of active GLP-1 and GIP in the circulation leading to improved beta-cell sensitivity to glucose and glucose-dependent insulin secretion, and improved alpha-cell sensitivity to glucose and reduction in inappropriate glucagon secretion. Vildagliptin 162-174 dipeptidyl peptidase 4 Homo sapiens 77-82 18269436-4 2008 Mechanistic studies of vildagliptin performed to characterise the effects of DPP-4 inhibition on pancreatic islet function and glucose metabolism have found that vildagliptin produces dose-dependent reductions in DPP-4; these result in persistent levels of active GLP-1 and GIP in the circulation leading to improved beta-cell sensitivity to glucose and glucose-dependent insulin secretion, and improved alpha-cell sensitivity to glucose and reduction in inappropriate glucagon secretion. Vildagliptin 162-174 dipeptidyl peptidase 4 Homo sapiens 213-218 18269436-1 2008 Vildagliptin is a potent, selective and reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for rapid inactivation of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 88-93 18640590-2 2008 Orally administered DPP-4 inhibitors, such as sitagliptin and vildagliptin, reduce HbA(1c) (absolute values) by 0.5-1.1% (5 to 12%, relative values), with few adverse events and no weight gain. Vildagliptin 62-74 dipeptidyl peptidase 4 Homo sapiens 20-25 18640591-2 2008 This review tries to delineate how to insert the GLP-1 based agents, DPP4-inhibitors (sitagliptin and vildagliptin) and GLP-1 analogues (exenatide and liraglutide), in the guidelines and the daily practice for the management of type 2 diabetes (T2DM). Vildagliptin 102-114 dipeptidyl peptidase 4 Homo sapiens 69-73 18840004-12 2008 The DPP-4 inhibitors sitagliptin and vildagliptin are generally weight neutral, with less marked gastrointestinal adverse effects than the GLP-1 receptor agonists. Vildagliptin 37-49 dipeptidyl peptidase 4 Homo sapiens 4-9 18941490-3 2008 The synthesized pyrrolidine derivative was utilized to prepare DPP-IV inhibitor Vildagliptin. Vildagliptin 80-92 dipeptidyl peptidase 4 Homo sapiens 63-69 17909087-0 2008 The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Vildagliptin 37-49 dipeptidyl peptidase 4 Homo sapiens 4-26 17909087-1 2008 OBJECTIVE: To evaluate the effect of treatment with the dipeptidyl peptidase (DPP)-4 inhibitor vildagliptin on insulin sensitivity and beta-cell function in subjects with impaired fasting glucose (IFG). Vildagliptin 95-107 dipeptidyl peptidase 4 Homo sapiens 56-84 17909087-10 2008 CONCLUSIONS: The DPP-4 inhibitor vildagliptin improves insulin sensitivity and beta-cell function, leading to improved postprandial glycemia in subjects with IFG, who are known to have beta-cell dysfunction. Vildagliptin 33-45 dipeptidyl peptidase 4 Homo sapiens 17-22 18042650-0 2008 Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. Vildagliptin 96-108 dipeptidyl peptidase 4 Homo sapiens 63-85 18042650-1 2008 OBJECTIVE: Pharmacological inhibition with the dipeptidyl peptidase 4 (DPP-4) inhibitor vildagliptin prolongs the action of endogenously secreted incretin hormones leading to improved glycemic control in patients with type 2 diabetes mellitus (T2DM). Vildagliptin 88-100 dipeptidyl peptidase 4 Homo sapiens 47-69 18042650-1 2008 OBJECTIVE: Pharmacological inhibition with the dipeptidyl peptidase 4 (DPP-4) inhibitor vildagliptin prolongs the action of endogenously secreted incretin hormones leading to improved glycemic control in patients with type 2 diabetes mellitus (T2DM). Vildagliptin 88-100 dipeptidyl peptidase 4 Homo sapiens 71-76 18947259-12 2008 Clinical evidence suggests that the DPP-4 inhibitors vildagliptin and sitagliptin are particularly suitable for frail and debilitated elderly patients because of their excellent tolerability profiles. Vildagliptin 53-65 dipeptidyl peptidase 4 Homo sapiens 36-41 18973400-1 2008 Vildagliptin (Galvus) is an antihyperglycaemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 83-105 18973400-1 2008 Vildagliptin (Galvus) is an antihyperglycaemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 107-112 18561513-2 2008 Most clinical experience with DPP-4 inhibition is based on vildagliptin (GalvusR, Novartis) and sitagliptin (JanuviaR, Merck). Vildagliptin 59-71 dipeptidyl peptidase 4 Homo sapiens 30-35 18827867-1 2008 Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-4), orally active, that improves glycemic control in patients with type 2 diabetes (T2DM) primarily by enhancing pancreatic (alpha and beta) islet function. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 52-75 18827867-1 2008 Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-4), orally active, that improves glycemic control in patients with type 2 diabetes (T2DM) primarily by enhancing pancreatic (alpha and beta) islet function. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 77-82 19337535-1 2008 Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through inhibition of dipeptidyl peptidase-4 (DPP-4), the enzyme that normally inactivates incretin hormones. Vildagliptin 16-28 dipeptidyl peptidase 4 Homo sapiens 142-164 19337535-1 2008 Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through inhibition of dipeptidyl peptidase-4 (DPP-4), the enzyme that normally inactivates incretin hormones. Vildagliptin 16-28 dipeptidyl peptidase 4 Homo sapiens 166-171 17931461-1 2007 BACKGROUND: Vildagliptin is an orally active, potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4), the enzyme responsible for the degradation of incretin hormones. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 80-103 17931461-1 2007 BACKGROUND: Vildagliptin is an orally active, potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4), the enzyme responsible for the degradation of incretin hormones. Vildagliptin 12-24 dipeptidyl peptidase 4 Homo sapiens 105-110 17656620-1 2007 Vildagliptin is a potent and selective dipeptidyl peptidase IV inhibitor in development for the treatment of type 2 diabetes that improves glycemic control by enhancing alpha- and beta-cell responsiveness to glucose. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 39-62 17992639-0 2007 Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Vildagliptin 114-126 dipeptidyl peptidase 4 Homo sapiens 98-103 17992639-1 2007 The aim of this study was to evaluate the contribution of insulin processing to the improved meal-related B-cell function previously shown with the DPP-4 inhibitor vildagliptin. Vildagliptin 164-176 dipeptidyl peptidase 4 Homo sapiens 148-153 18632049-2 2007 Another DPP4 inhibitor vildagliptin is due to be launched soon, and there are several others in the pipeline. Vildagliptin 23-35 dipeptidyl peptidase 4 Homo sapiens 8-12 17698900-0 2007 The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. Vildagliptin 37-49 dipeptidyl peptidase 4 Homo sapiens 4-26 17698900-1 2007 BACKGROUND/AIMS: Inhibition of dipeptidyl peptidase 4 by vildagliptin enhances the concentrations of the active form of the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP). Vildagliptin 57-69 dipeptidyl peptidase 4 Homo sapiens 31-53 17877545-0 2007 The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. Vildagliptin 20-32 dipeptidyl peptidase 4 Homo sapiens 4-9 17877545-1 2007 Vildagliptin is a potent selective inhibitor of dipeptidyl peptidase-4 (DPP-4) that improves glycaemic control by increasing islet alpha-cell and beta-cell responsiveness to glucose. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 48-70 17877545-1 2007 Vildagliptin is a potent selective inhibitor of dipeptidyl peptidase-4 (DPP-4) that improves glycaemic control by increasing islet alpha-cell and beta-cell responsiveness to glucose. Vildagliptin 0-12 dipeptidyl peptidase 4 Homo sapiens 72-77 17877545-7 2007 The overall profile of vildagliptin and the preliminary evidence of beneficial effects in the prediabetic state suggest that DPP-4 inhibition could be an effective strategy to prevent or delay progression from the prediabetic state to overt T2DM. Vildagliptin 23-35 dipeptidyl peptidase 4 Homo sapiens 125-130 30736119-0 2007 DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. Vildagliptin 84-96 dipeptidyl peptidase 4 Homo sapiens 0-5 30736119-6 2007 The focus of the review is on one of the DPP-4 inhibitors, vildagliptin, since there is much recently published data on this drug. Vildagliptin 59-71 dipeptidyl peptidase 4 Homo sapiens 41-46 17656620-0 2007 Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Vildagliptin 47-59 dipeptidyl peptidase 4 Homo sapiens 69-92